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INTRODUCTION
Development of new drugs is difficult, expensive and rather time consuming, as it involves the  
processes like  preclinical testing, investigational new drug application (IND), clinical trials, phase I, II, & 
III,  new drug application (NDA) and FDA approval.   Improving safety and efficacy of existing drugs is 
being  attempted  by  using  different  methods  such  as  individualizing  drug  therapy,  dose  titration  and 
therapeutic drug monitoring and, most importantly, delivering drugs at controlled rates at targeted sites. 
Drug  delivery  systems  could  provide  extended  circulating  half-lives  so  that  less  drug  is  required  for 
therapeutic effectiveness relieving the patient from side effects caused by non-specific tissue uptake and 
provide protection against enzymatic degradation. 
Today, lipid and nonionic surfactant based drug delivery systems have drawn much attention from 
researchers  as  potential  carriers  of  various  bioactive  molecules  that  could  be  used  for  therapeutic 
applications. Several commercial liposome/niosome-based drugs have already been marketed with a great 
success. For example, liposomes and niosomes have been used to encapsulate Colchicines,1 Tretinoin,2,3 
Dithranol,4 Enoxacin,5  Estradiol,6 Methotrexate7  for applications such as anticancer, anti-tubercular, anti-
leishmanial, anti-inflammatory, hormonal drugs and oral vaccines. 8-15 
Liposomes  have  been  reported  to  increase  drug  stability,  enhance  therapeutic 
effects, prolong circulation time and promote uptake of the entrapped drugs into target 
site  while  drug  toxicity  is  diminished.  However,  there  are  problems  in  the  general 
applications  of  liposomes.  In an aqueous system,  liposomes have problems regarding 
degradation by hydrolysis  of phospholipid molecules.  Problems with the physical and 
chemical stabilities of aqueous suspensions of liposomes have been addressed by many 
researchers,  who  introduced  a  dry  free-flowing  granular  product  that  could  be 
immediately  hydrated  before  use. One  alternative  of  phospholipids  is  the  hydrated 
mixture of cholesterol and non-ionic surfactants such as alkyl ethers, alkyl esters or alkyl 
amides non-ionic surfactants. This type of vesicle formed from the above mixture has 
been known as niosomes or non-ionic surfactant vesicles.16 Here we are concerned about 
the ocular delivery of the drug by vesicular system.
1. Ophthalmic drug delivery16
An ophthalmologist prefer topical application to the eye as a method of treating 
eye diseases since systemic involvement is usually, but not always minimal. For some 
drugs such as  anti-cholinesterase  and most  cholinergic  drug,  treatment  of  the  eye  by 
systemic  route  would  be  impossible  because  of  their  toxicity.  Most  of  the  current 
ophthalmic  preparations  are  available  as  sterile  buffered isotonic solutions,  because a 
majority  of  ophthalmic  drugs  are  water  soluble.  In  fact  solution  dosage  forms  are 
preferred, as drops are easier to administer. However in situation where there is solubility 
limitation, or when a prolonged action is desired, disperse system such as suspension, 
gelled system and ointment are indicated
The  unique  anatomy,  physiology  and  biochemistry  of  eye  tenders  this  organ 
exquisitely impervious to foreign substance, thus presenting a constant challenge to the 
formulator to circumvent the protective barrier of the eye without causing any permanent 
tissue  damage.  Currently  the  knowledge  in  this  field  is  rapidly expanding and many 
concepts and drug delivery strategies are emerging out.
1.1. Eye: Anatomical and physiological overview 17
The  human  eye  has  spherical  shape  with  23  mm  diameter.  The  structural 
components of the ball are divided in to three layers. 
1. The outer most coat of clear transparent cornea and white opaque sclera 
2. The middle layer comprises the iris anteriorly, the choroids posteriorly and ciliary 
body as intermediate part; and
3. The inner layer is the retina which is an extension of the central nervous system.
The fluid systems in the eye, aqueous humor and vitreous humor also plays an 
important role in maintaining ocular pressure. Cornea is optically transparent tissue that 
acts as the principle refractive element of the eye. The corneal diameter is about 11.7 mm 
with a radius of curvature (anterior surface) about 7.8 mm. The corneal thickness is 0.5-
0.7 mm and it is thicker in the center. The cornea is composed of epithelium, bowmen’s 
membrane, strauma, descement’s membrane and endothelium. The relative thickness of 
corneal  epithelium  (50-90mm),  strauma  and  endothelium  are  about  0.1,  1.0  &  0.01 
respectively.  The shape of cornea and lens adjusted by ciliary body. A mesh of blood 
vessels, the choroids supplies oxygen and glucose to the retina. Lachrymal gland secrets 
tear  that  wash foreign  bodies  out  of  and  keep the  cornea  from drying  out.  Blinking 
compresses  the  lachrymal  sac  and  allows  the  lachrymal  fluid  to  move  out  which 
moistures  the  eye  surface.  The drugs  in  ophthalmic  preparation  reach inside  the  eye 
through  cornea,  because  the  structure  of  cornea  consists  of  epithelium–strauma–
endothelium, which is equivalent to a fat-water-fat system. The penetration of non polar 
compound through the cornea depends on their oil/water partition coefficient.
The  blood  ocular  barrier  normally  keeps  most  drugs  out  of  eye.  However 
inflammation breaks down this barrier allowing drug and large molecule to penetrate in 
to the eye. As the inflammation subsides the barrier will return.
The blood barrier comprises the following sites. 
1. The aqueous humor blood barrier between the ciliary epithelium and capillaries of 
iris 
2. Blood retinal  barrier:  Non-fenestrated  capillaries  of  the  retinal  circulation  and 
tight junction between retinal epithelial cell preventing passages of the large molecule 
from choroid capillaries of retina.
1.2. Absorption of drug in eye 18-20  
It is often assumed that drugs administered in to the eye are totally and rapidly 
absorbed however these are few factors which affect the drug delivery to eye. Absorption 
of  drug takes  place  in  corneal  or  non corneal  route.  The  non corneal  route  involves 
absorption  across  the  sclera  and  conjunctiva  which  restrains  the  entry  of  drug  into 
aqueous humor. Maximum absorption takes place in cornea which leads drug to aqueous 
humor. A big portion of the drug that administered to the eye was lost leading to poor 
ocular bioavailability.
1.2(a) Drug elimination from lachrymal fluid 
Drugs  are  mainly  eliminated  from the  precorneal  lachrymal  fluid  by  solution 
drainage, lacrimation and non productive absorption by conjunctiva of the eye. Only little 
percentage of applied doses delivered in to intra ocular tissue, while the major part (50-
100%) of dose is absorbed systemically. The pre-corneal constraints include: 
1. Dilution of drug by over flow 
2. Dilution of drug by tear turn over 
3. Nasolachrymal drainage conjunctival absorption 
4. Enzyme metabolism 
Fig 1 Schematic presentation of the ocular structure with the routes of drug kinetics  
illustrated. The numbers refer to following processes: 1) Tran corneal permeation from 
the lachrymal fluid into the anterior chamber, 2) Non-corneal drug permeation across the 
conjunctiva and sclera into the anterior urea, 3) Drug distribution from the blood stream 
via blood-aqueous barrier  into the anterior  chamber,  4) Elimination  of drug from the 
anterior  chamber  by  the  aqueous  humor  turnover  to  the  trabecular  meshwork  and 
Sclemm's  canal,  5)  Drug  elimination  from  the  aqueous  humor  into  the  systemic 
circulation across the blood-aqueous barrier, 6) Drug distribution from the blood into the 
posterior eye across the blood-retina barrier, 7) Intravitreal drug administration, 8) Drug 
elimination from the vitreous via posterior route across the blood-retina barrier, and 9) 
Drug elimination from the vitreous via anterior route to the posterior chamber. 
1.2(b) Transcorneal penetration 
Trans-corneal  penetration  mainly  affected  by  corneal  barrier,  physicochemical 
properties of drug and active ion transport system present at cornea.  Corneal epithelium 
is the main barrier for drug absorption in the eye. The stratified corneal epithelium act as 
a  protective  barrier  against  invasion  of  foreign  molecule  and  also  a  barrier  to  ion 
transport.  In  a  healthy  corneal  epithelium  trans-cellular  tight  junction  completely 
surround the most super facial cells. A tight junction serves as selective barrier for small 
molecules and they completely prevent the diffusion of macromolecules via Para cellular 
route, were as small molecules are able to penetrate through intercellular space of corneal 
epithelium. Corneal stroma is a highly hydrophilic tissue containing mostly water, and is 
a  relatively  open  structure.  Corneal  stroma  penetration  rate  is  rate  limiting  step  for 
lipophilic drug.
Hydrophilic  drug  penetrate  primarily  through  Para  cellular  pathway  which 
involves passive and active diffusion, while lipophilic drug prefers Trans-cellular route. 
For a topically applied drug passive diffusion by Trans-cellular/Para-cellular way is the 
main  mechanism  of  permeation.  Lipophilicity  solubility,  molecular  size,  charge  and 
degree of ionization also affect the route and rote of penetration in cornea. 
Various enzymes present in ocular tissue (protease, peptidase, and esterase) may 
metabolize  many  of  ocular  drugs  during  or  after  absorption.  The  corneal  epithelium 
contains  ionic  channels  that  are  selective  for  cation  over  anion and also  contains  an 
outwardly  rectifying  anion  channel  in  the  apical  membrane  and  highly  conductive 
potassium channel.
1.2(c) Non corneal absorption
This route involves drug penetration across the bulbar conjunctiva and underlying 
sclera in to the uveal tract and vitreous humor. This route is important for hydrophilic and 
large molecule with poor corneal permeability. 
Tight  junctions  of  spherical  conjunctival  epithelium  are  main  barrier  of  drug 
penetration. conjunctival permeability of particular drug have magnitude higher than that 
of corneal  penetration through sclera is mainly through perivascular spaces, through the 
aqueous  media  of  gel  like  mucopolysaccharide  or  through  spaces  between  collagen 
network. Sclera has more permeability compare to cornea. 
1.3. Conventional ocular delivery constrains 
For  the  ailments  of  the  eye,  topical  administration  is  usually  preferred  over 
systemic administration so as to avoid systemic toxicity, for rapid onset of action, and for 
decreasing the required dose. Though topical administration offers many advantages to 
treat disorders of anterior structures of the eye, it suffers from a serious disadvantage of 
poor bioavailability due to several biological factors (Fig. 1), which exist to protect the 
eye and consequently limit the entry of ocular drugs. The constraints in topical delivery 
of the eye are discussed below.
Fig .2. Factors attributing to poor bioavailability of an ophthalmic formulation.
1.4. Disadvantage of topical ophthalmic formulations.
The conventional topical ophthalmic preparations have the following disadvantages.
1) They have poor bioavailability because of 
a. Rapid precorneal elimination 
b. Conjunctival absorption 
c. Solution drainage by gravity
d. Induced lacrimation 
e. Normal tear turn over
2) Frequent  instillation  of concentrated  medication  is  required to  achieve  therapeutic 
effect.
3) Systemic absorption of drug and additives drained through nasolachrymal duct may 
result in undesirable effect. 
4) The amount of drug delivered during external application may vary. The drop size of 
ocular medication is not uniform and dose delivered is generally not correct.
1.5. Requisites of controlled ocular delivery system  
1. To over come the side effects of pulsed dosing (frequent dosing) and high 
concentration produced by conventional system. 
2. To provide sustained and controlled drug delivery.
3. To increase the ocular  bioavailability  of  drug by increasing cornel  contact 
time. This can be achieved by effective coating or adherence to corneal surface, 
so that the released drug effectively reaches the anterior chamber.
4. To provide targeting within the ocular globe so as to prevent the loss to other 
ocular diseases.
5. To circumvent the protective barrier like drainage, lacrimation and diversion 
of exogenous chemicals into the systemic circulation by the conjunctiva.
6. To  provide  comfort  and  compliance  to  the  patient  and  yet  improve  the 
therapeutic performance of the drug over conventional system. 
7. To improve the better housing of the delivery system in the eye so as the loss 
to other tissues besides cornea is prevented.
Ocular drugs and delivery system are currently undergoing a process of design 
optimization due to inherent physiological and anatomical constraints of the eye leading 
to limited absorption topically applied drug. 
1.6. Formulation approaches to improve ocular bioavailability
Various approaches that have been attempted to increase the bioavailability and 
the duration of therapeutic action of ocular drugs can be divided into two categories. The 
first is based on the use of the drug delivery systems, which provide the controlled and 
continuous delivery of ophthalmic drugs. The second involves, maximizing corneal drug 
absorption  and  minimizing  precorneal  drug  loss.  The  conventional  ocular  aqueous 
solutions (eye drops), suspensions and ointments can be replaced by a more controlled, 
sustained and continuous drug delivery, using a controlled release ocular drug delivery 
system. These systems can achieve therapeutic action with a smaller dose and a fewer 
systemic and ocular side effects.  Such systems include implantable systems,  ocuserts, 
collagen  shields  etc.,  but  the  limitations  of  these  systems  include  poor  patient 
compliance, need of surgery, and difficulty in self-insertion.
 Particulate drug delivery systems, like nanoparticles and microspheres, can also 
be used to improve the residence time of the drug. Upon administration to the eye, the 
particles reside at the delivery site and the drug is released from the particles through 
diffusion, chemical reaction, polymer degradation or ion-exchange mechanism. Smaller 
particles are better tolerated by the patients than larger particles and hence microspheres 
and nanoparticles represent very comfortable prolonged action ophthalmic drug delivery 
systems. However, some workers observed that nanoparticles consisting of poly (alkyl 
cyanoacrylate) damaged the corneal epithelium by disrupting the cell membrane.
Capacity of some polymers to adhere to the mucin coat covering the conjunctiva 
and the corneal surfaces of the eye by a non-covalent bond  has been exploited to provide 
an intimate contact between the drug and the absorbing tissue, which may result in high 
drug concentration in the local area and hence, drug flux through the absorbing tissue 
Common disadvantage observed is that the adhesive often detaches itself from the rate 
controlling drug delivery device and causes premature release of drugs.
Even though various drug delivery systems mentioned above offer a numerous 
advantages  over  conventional  drug  therapy  but  still  they  are  not  devoid  of  pitfalls, 
including
• Poor patient compliance and difficulty of insertion as in ocular inserts,
• Tissue irritation and damage caused by penetration enhancers and collagen 
shields,
• Toxicity caused by insertion of foreign substances, like albumin and 
polybutylcyanoacrylate, as in case of nanoparticles and microspheres
• Change in pharmacokinetic and pharmacodynamics of the drug as caused by 
altering the chemical structure of the drug (prodrug approach).
In order  to  overcome these  problems,  the  researchers  have  come up with  the 
concept  of  vesicular  drug  delivery  systems  as  applied  to  corneal  delivery.  Vesicular 
delivery is  a  means of prolonged and controlled  delivery.  Drug enclosed in the lipid 
vesicles allows for an improved solubility and transport through the cornea. 
1.7. Vesicular system in ocular delivery 21
Vesicular systems not only help in providing prolonged and controlled action at 
the corneal surface but also help in providing controlled ocular delivery by preventing the 
metabolism of the drug from the enzymes present at the tear/corneal epithelial surface. 
Moreover, vesicles offer a promising avenue to fulfill the need for an ophthalmic drug 
delivery system that has the convenience of a drop, but will localize and maintain drug 
activity  at  its  site  of  action.  The  penetration  of  drug molecules  into  the  eye  from a 
topically  applied preparation is  a complex phenomenon.  The rate  of drug penetration 
depends  not  only  on  the  physicochemical  properties  of  the  drug  itself,  such  as  its 
solubility and particle size, in case of suspensions but also on those of its vehicle.  In 
vesicular dosage forms, the drug is encapsulated in lipid/surfactant vesicles, which can 
cross cell membrane. Vesicles therefore can be viewed as drug carriers and as such they 
change the rate and extent of absorption as well as the disposition of the drug. Vesicular 
drug  delivery  systems  used  in  ophthalmic  delivery  broadly  include  liposomes  and 
niosomes.
1.7.1. Liposomes
Liposomes are the microscopic vesicles composed of one or more concentric lipid 
bilayers,  separated by water or aqueous buffer compartments with a diameter  ranging 
from 80 nm to 10 nm. Liposomes were first described by Bangham et al.  Such vesicles 
composed of one or more phospholipid bilayer membranes can entrap both hydrophilic 
and hydrophobic drugs, depending on the nature of the drug and hence, it is possible to 
apply water-insoluble drugs in liquid dosage form. According to their size, liposomes are 
known as  either  small  unilamellar  vesicles  (SUV) (10–100  nm)  or  large  unilamellar 
vesicles  (LUV) (100–3000 nm).  If  more  than  one bilayers  are  present,  then they are 
referred to as multilamellar vesicles. Liposomes offer advantages over most ophthalmic 
delivery systems in being completely biodegradable and relatively non-toxic.  Another 
potential advantage of liposomes is their ability to come in an intimate contact with the 
corneal  and  conjunctival  surfaces,  thereby  increasing  the  probability  of  ocular  drug 
absorption.  This ability is especially desirable  for drugs that are poorly absorbed, for 
example, the drugs with low partition coefficient, poor solubility or those with medium to 
high molecular weights. Despite the above discussed factors, which make liposomes a 
potentially useful system for ocular delivery they are not very popular because of their 
short shelf life, limited drug capacity, and problems in sterilization. The latter problems 
can be taken as challenge to establish liposomes as an effective means of ocular delivery.
1.7.2. Niosomes.
Non-ionic surfactant based vesicles (niosomes) are formed from the self-assembly 
of non-ionic amphiphiles in aqueous media resulting in closed bilayer structures (Fig. 4). 
The assembly into closed bilayers is rarely spontaneous and usually involves some input 
of energy such as  physical  agitation  or heat.  The result  is  an assembly in which the 
hydrophobic  parts  of  the  molecule  are  shielded  from  the  aqueous  solvent  and  the 
hydrophilic  head  groups  enjoy  maximum  contact  with  same.  These  structures  are 
analogous  to  phospholipid  vesicles  (liposomes)  and  are  able  to  encapsulate  aqueous 
solutes and serve as drug carriers. The low cost, greater stability and resultant ease of 
storage  of  non-ionic  surfactants  has  lead  to  the  exploitation  of  these  compounds  as 
alternatives to phospholipids. Niosomes were first reported in the seventies as a feature of 
the  cosmetic  industry  but  have  since  been  studied  as  drug  targeting  agents. These 
formulations use alternative materials  to phospholipids such as Span 60, Span 40 and 
Span 20 which are inexpensive and widely available permitted food additives.  
                              
Fig. 3. Schematic representation of a niosome & 3-dimension structure
Niosomes are essentially nonionic surfactant based multilamellar or unilamellar 
vesicles  in  which  an  aqueous  solution  of  solute  is  entirely  enclosed  by a  membrane 
resulted  from  the  organization  of  surfactant  macro  molecule  as  bilayer.  Similar  to 
Liposome,  niosomes  are  formed  on  hydration  of  nonionic  surfactant  film,  which 
eventually hydrates imbibing or encapsulating the hydrating aqueous solution. Compared 
to  phospholipids  used  in  the  Liposome,  the  synthetic  non  ionic  surfactants  used  in 
Niosome preparation are chemically stable, precise in chemical composition and cheaper 
in cost.
1.7.2(a) Physicochemical aspects of non ionic surfactant21 
Structural components of niosomal bilayer 
L’Oreal  reported  alkyl  and  dialkyl  poly  glycerol  ethers  as  vesicles  forming 
nonionic  surfactant.  Muller  and  Goymann  1987  investigated  bilayer  forming 
characteristics  of  PEG-polyglycols  and  polyethylene  ethers  system.  Fig.4  shows  a 
schematic representation of amphiphiles. In certain cases cholesterol is required in the 
formulation and vesicle aggregation or example may be prevented by the inclusion of 
molecules that stabilize the system against the formation of aggregates by repulsive steric 
or electrostatic effects. An amphiphiles forming niosome must possess a hydrophilic head 
group and a hydrophobic tail. The hydrophobic moiety may consist of one or two alkyl or 
perfluoroalkyl groups or in certain cases a single steroidal group. The alkyl group chain 
length is usually from C12–C18. Molecules may possess one, two or three alkyl chains. 
Perfluoroalkyl  surfactants  that  form  vesicles  possess  chain  lengths  as  short  as  C10. 
Additionally  crown  ether  amphiphiles  bearing  a  steroidal  C14  alkyl  or  C16  alkyl 
hydrophobic unit have been shown to form vesicles. While the number of hydrophobic 
permutations is at present limited, there have been a wide variety of hydrophilic head 
groups in vesicle forming surfactants and it is in this area of vesicle forming surfactant 
design that considerable scope for new formulations still exist. The two portions of the 
molecule may be linked via ether, amide or ester bonds.  
                                   
                               Fig.  4. Schematic representation of an amphiphile 
We have observed that a parameter like the hydrophilic lipophilic balance (HLB) 
is a good indicator of the vesicle forming ability of any surfactant.  With the sorbitan 
monostearate  (Span)  surfactants,  a  HLB number  between  4  and  8  was  found  to  be 
compatible with vesicle formation. The guidance offered by the HLB number is useful as 
apart  from the  theoretical  methods  of  estimating  HLB number  in  which  the  relative 
proportions  of  both  the  hydrophilic  and  hydrophobic  portions  of  the  molecule  are 
assessed,  practical  methods  of  HLB number  determination  have  also  been  reported. 
These studies may be useful in the evaluation of new classes of compounds for their 
vesicle forming ability. The water soluble detergent polysorbate 20 also forms niosomes 
in the presence of cholesterol.   This is  despite  the fact that  the HLB number of this 
compound is 16.7 and it appears on first inspection to be too hydrophilic to form a bilayer 
membrane. However with an optimum level of cholesterol, it seems that niosomes are 
indeed  formed  from polysorbate.  Although  a  particular  membrane  surfactant  may be 
chosen by combining the hydrophilic moieties given in with an appropriate hydrophobic 
group. Established molecules may also be chosen from those mentioned in a few earlier 
reviews. Some of  these surfactants  such as  the Span and Brij  surfactants  are  already 
established  pharmaceutical  excipients.  Span  60  (C18)  and  Span  40  (C16)  gave  the 
greatest encapsulation efficiency for niosomes and were the least leaky niosomes due to 
the fact that these Span surfactants had the highest phase transition temperature.  Also 
unsonicated Span 60 niosomes gave the greatest encapsulation efficiency. With sonicated 
Span surfactant niosomes the encapsulation efficiency followed the trend C18\C16\C12.
Table no. 1
Chemical specification of span 20, 40, 60, cholesterol, dicetylphosphate, and CF
Chemical Specification Description MW (g/mol)
MW 
Formula HLB
Sorbitan monolaurate 
(Span20)
Clear viscous 
liquid 346.5 C18H34O6 8.6
Sorbitan monopalmitate 
(Span40) Yellowish power 402.6 C22H42O6 6.7
Sorbitan monostearate 
(Span60) White powder 430.6 C24H46O6 4.7
Cholestrol White powder 386.7 C27H46O N/A
Dicetyl Phosphate White powder 546.9 C32H67O4P N/A
5(6)-carboxyfluorescein Yellowish powder 376.0 C21H12O7 N/A
Membrane additives
Unfortunately the prediction of vesicle forming ability is not  simply a matter of 
HLB numbers and chemical structure various other factors come into play. It is generally 
accepted  that  the  parameters  for  self-assembly  laid  own by  Israelachvili  in  which  a 
critical packing parameter (CPP) was defined, largely hold true today.
                                            CPP=v/lc ao
Where v hydrophobic group volume, lc the critical hydrophobic group length and 
ao the area of the hydrophilic head group (fig. 4.). A CPP of between 0.5 and 1 (the area 
of head group between 0.25-0.5) indicates that the surfactant is likely to form vesicles. A 
CPP of below 0.5 (indicating a large contribution from the hydrophilic head group area) 
is said to give spherical micelles and a CPP of above 1 (indicating a large contribution 
from  the  hydrophobic  group  volume)  should  produce  inverted  micelles,  the  latter 
presumably only in an oil phase, or precipitation would occur. Often various additives 
must be included in the formulation in order to prepare stable niosomes, which may be 
formed by the manipulation of the membrane forming agents in a typical system. The 
most common additive found in niosomal systems is cholesterol. Thus in cases where a 
mixture of surfactants or cholesterol is used to prepare niosomes, the operational CPP 
values will be those of the entire components.
Fig.5. Chemical structure of span60 (A), span40 (B) and span20 (C)
Being amphipathic in nature cholesterol aligns itself in such a way the OH group 
orient  towards  aqueous phase while  aliphatic  chain  align  parallel  to  the  hydrocarbon 
chain  of  surfactant.  Further,  in  a  mixed  molecular  bilayer  it  occupies  an  alternative 
position. The presence of rigid steroidal skeleton along side the carbon chain of surfactant 
could  possibly  restrict  the  freedom  of  movement  of  the  carbon  of  the  hydrocarbon 
segment thus providing an absolute rigidization. Also, the addition of cholesterol enables 
more hydrophobic surfactants to form vesicles, suppresses the tendency of the surfactants 
to form aggregates, and lends greater stability to the bilayer membranes by raising the gel 
liquid transition temperature of the vesicle16. Below are the phase transition temperatures 
of  nonionic  surfactants.  As  in  the  case  of  liposome  the  lipophilicity,  temperature  of 
hydration and phase transitions temperature are of importance in the vesicle formation.  
Table no.2
Phase transition temperature of span 20, 40, and 60
Nonionic Surfactant Acyl composition Gel Transition Temperature
Sorbitan monolaurate (Span20) C9 Liquid at room temperature
Sorbitan monopalmitate (Span40) C13 46-47oC
Sorbitan monostearate (Span60) C15 56-58oC
1.7.2(b) Methods of Preparation 
Ether injection 
The ether injection method essentially based on the slow injection of surfactant: 
cholesterol solution in ether through a 14 gauge needle at rate approximately 0.25 ml/min 
in to a preheated 4.0 ml aqueous phase maintained at 600  C. Fluorinated hydrocarbon 
evaporate at much lower temperature could be substituted ether in case where drug to be 
incorporated  are  highly  susceptible  to  temperature.  The variation  in  vesicular  size  in 
aqueous  phase  may  be  varied  by  an  additional  addition  of  the  ethereal  solution  of 
surfactant whilst effective volume dispersion remains to be constant.
Hand shaking 
Surfactant and cholesterol mixture in molar ratio dissolved in suitable quantity of 
organic solvent (diethyl ether, chloroform, alcohol) in around bottom flask. The ether is 
evaporated  under  vacuum  at  room  temperature  in  a  rotary  flash  evaporator.  Upon 
hydration  the  surfactant  swells  and  peeled  of  the  support  in  to  a  film.  The  swollen 
amphiphiles eventually folds in to vesicles. The liquid volume entrapped into the vesicles 
appears small 5-10%. The entrapable volume seems to be unsuitable for water soluble 
drugs  although  the  absolute  yield  per  ml  of  solution  per  gram of  surfactant  may  be 
satisfactory for practical purpose. 
Sonication
Niosomes using sonications method prepared by baille et al where 150µ mol of 
surfactant  cholesterol  mixture was dispersed in 2 ml of aqueous phase in a vial.  The 
dispersion was probe sonicated for 3 min at 600  C. essentially; the method involves the 
formation  of  MLVs  which  are  subsequently  subjected  to  ultrasonic  vibration.  Probe 
sonaicator could be used if the sample size is small.  However for large samples bath 
sonaicator is considered to be suitable. The finished vesicles are unilamellar in shape. 
Great care must be taken while working with temperature sensitive solute.
Reverse phase evaporation
Surfactants are dissolved in chloroform and 0.25 ml phosphate buffer saline is 
emulsified  to  get  w/o  emulsion.  The  mixture  is  then  sonicated  and  subsequently 
chloroform is  evaporated  under  reduced  pressure.  The  surfactant  forms  gel  first  and 
subsequently hydrates to form vesicles.     
Aqueous dispersion
The method deals with dispersion of vesicle forming agent and active drug which 
is subsequently homogenized at room temperature followed by continuous bubbling of 
nitrogen  till  the  vesiculation  or  hydration  completed.  The  bubbles  possibly  provide 
spherical gas at interface for amphiphiles to get organized as per thermodynamic stability 
requirements. Nitrogen is released subsequently and allows hydration of amphiphiles to 
form vesicles.
Extrusion  
Niosomes prepared using C16 G12 a chemically defined non ionic surfactant by 
extrusion through a poly carbonate membrane (0.1 µm). It was found that using extrusion 
technique vesicle of mean size 138 nm could be prepared. 
Separation of niosomes
The aqueous dispersion of solute bearing niosomes prepared by one of the above 
described method and is exhaustively dialyzed using cellophane tubing against phosphate 
buffer  saline.  The  column  chromatographic  method  also  used  for  the  separation  of 
niosome from the free drug containing niosomal suspension. For vesicular systems, in 
order to make them free of the free drug sephadex G50 is commonly employed. The drug 
is preferentially retained in the column while vesicles percolate down the column.  
1.7.2(c) Encapsulation efficiency and solute release rate                          
There  is  no  successful  and  satisfactory  study  which  shows  a  theoretical 
correlation of the entrapment efficiency of hydrophilic and hydrophobic solute within the 
niosomal  vesicles.  This  is  partly  due  to  the  method  of  preparation  and  subsequent 
processing of the system. However encapsulation efficiency can be said as a product of 
the stability of the dispersion. That is, the encapsulated solute and the solute retention 
capability  of  the  encapsulating  membrane,  together  with  the  stability  of  both  the 
surfactant and vesicle structure, all contributes to the stability of the formulation. Vesicle 
loaded by trans-membrane gradient method shows higher entrapment efficiency.  As a 
rule  larger  vesicles  have  higher  entrapment  compared  to  smaller  one.  Water  soluble 
solutes results in increased vesicle size.
Encapsulation efficiency is a measure of solute retention and cholesterol has been 
shown to assist solute retention. The amount cholesterol also decides the release rate the 
extent  of  solute  from the vesicle.  Nevertheless  there  are  some reports  which show a 
decrease in the entrapment on inclusion of cholesterol. Similarly vesicles formed from 
the  polyoxyethylene  1,  2  disteroyl  ether  did  not  show  any  significant  influence  on 
encapsulation efficiency on inclusion of cholesterol. 
The alky chain length also found to have clear influence on entrapment efficiency, 
as the chain length increases better the encapsulation of solute. An increase in the alky 
chain length of surfactant also found to show a gradual decrease in the vesicle size. The 
presence of  surface charge on the vesicular  dispersion is  critical  as it  determines  the 
aggregation  character  of  the  vesicles.  Vesicular  surface  charge  can  be  estimated  by 
measurement of particle electrophoretic mobility and is expressed as zeta potential.
1.7.2(d) Niosome stability
Stable niosome dispersion must  exhibit  a constant  particle  size and a constant 
level of entrapped drug. There must be no precipitation of the membrane components, 
which are to a large extent not insoluble in aqueous media. It appears that the original  
size of the formulation has an effect on the stability of the system. This is in keeping with 
thermodynamic theory as the smaller niosomes require a higher input of energy and thus 
contain more excess energy and an inherently greater instability than the larger niosomes 
prepared by hand shaking. A further example of how the method of vesicle formation has 
important bearing on the stability of these systems is the fact that vesicles prepared by the 
solvent injection method (ethanol) are found to have an additional phase transition due to 
the  presence  of  residual  ethanol.  A  number  of  membrane  properties  rely  on  the 
temperature of the main phase transition such as the membrane permeability and rigidity. 
The  introduction  of  membrane  defects  due  to  the  presence  of  residual  ethanol  may 
destabilize these drug delivery systems. The addition of cholesterol found to increase the 
stability of the niosomal system by decreasing the leakage of system. The observed effect 
of cholesterol is in accordance with the membrane stabilizing effect. Cholesterol found to 
decrease  the fluidity  of  membrane which leads  to  membrane  stabilization.  It  may be 
possible  to  stabilize  niosomes  by  a  variety  of  methods  such  as  the  addition  of 
polymerized surfactants to the formulation, the use of membrane spanning lipids and the 
interfacial polymerization of surfactant monomers in situ. 
1.7.2(e) Ocular Delivery 16
Niosomes in topical ocular delivery are preferred over other vesicular systems because:
(i) They are chemically stable as compared to liposomes.
(ii) They can entrap both lipophilic and hydrophilic drugs.
(iii) They have low toxicity because of their non-ionic nature.
(iv) Unlike phospholipids, handling of surfactants requires no special 
precautions and conditions.
(v) They exhibit flexibility in their structural characterization, e.g. in 
their composition, fluidity, and size.
(vi) They  can  improve  the  performance  of  the  drug  via  better 
availability and controlled delivery at a particular site.
(vii) They are biodegradable, biocompatible, and non-immunogenic.
An increased ocular bioavailability of water-soluble drugs entrapped in niosomes, 
(where liposomes are favorable as carrier system only for hydrophobic drugs) may be due 
to  the  fact  that  surfactants  (chief  constituents  of  niosomes)  also  act  as  penetration 
enhancers  as  they can  remove the mucus  layer  and break junctional  complexes.  The 
irritation power of surfactants decreases in the following order:  cationic  >  anionic  > 
ampholytic > non-ionic so the non-ionic surfactants are preferred. The modified form of 
niosomes  known  as  discomes  is  also  used  in  ophthalmic.  The  non-ionic  surfactant 
vesicles  have  been reported  to  be successful,  as  an ocular  vehicle  for  cyclopentolate 
independent of the pH, significantly improved the ocular bioavailability of cyclopentolate 
with respect to reference buffer solution and no irritation with the niosomal formulation 
was observed. Vyas et al20 reported that there was an increase in the ocular bioavailability 
of timolol maleate encapsulated in niosomes as Compared to timolol maleate solution.
Drugs that could be considered for ocular delivery by vesicular systems, includes 
to anti glaucoma drugs, antibiotics and anti inflammatory (NSAIDS), which used in the 
treatment of anterior eye inflammation. The other drug includes the antiviral, antifungal 
and antiallergics. 
REVIEW OF LITERATURE
1. Literatures on Vesicular Systems in Drug Delivery.
Jain et al., 22 prepared Rifampicin niosome for lymphatic delivery using sorbitan 
esters and cholesterol 50:50. The drug entrapped vesicles characterized for their shape 
size and the drug entrapment efficiency and in vitro release, cumulative percent dose of 
drug in the lymphatic on intra peritoneal administration and intra venous administration 
were compared.  The study revealed effective compartmentalization of drug after intra 
peritoneal administration of the niosome and the niosome could be successfully used for 
effective treatment if the tuberculosis along lymphatic. 
Manosroi et al., 15 studied on vesicles (niosomes) prepared with hydrated mixture 
of  various  non-ionic  surfactants  and  cholesterol.  The  entrapment  efficiencies  of  the 
vesicles and micro viscosities of the vesicular membrane depended on alkyl chain length 
of non-ionic surfactants and amount of cholesterol used to prepare vesicles. The stearyl 
chain (C18) non-ionic surfactant vesicles showed higher entrapment efficiency than the 
lauryl  chain  (C12)  non-ionic  surfactant  vesicles.  Niosome  prepared  with  Tween  61 
bearing  a  long  alkyl  chain  and  a  large  hydrophilic  moiety  in  the  combination  with 
cholesterol at  1:1 molar ratio was found to have the highest entrapment efficiency of 
water soluble substances.
Lakshmi et al., 23 studied on a novel formulation of niosome 0.25% methotrexate 
using a polymer Chitosan, which administered once daily for 12 weeks in comparison 
with placebo in patients with palmoplantar psoriasis. The results shows that the lesions 
treated with Niosomal Chitosan-Methotrexate formulation showed marked improvement 
in comparison to plain methotrexate and placebo gel in spite of twice a day application.  
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The results concludes that the 0.25% niosomal Methotrexate in Chitosan gel exhibited 
beneficial effect in psoriasis and did not exert any systemic toxicity.
Uchegbu et al.,9 have prepared Doxorubicin niosomes (10 mg kg-1 doxorubicin) 
from  sorbitan  monostearate  (Span  60),  cholesterol  and  choleth-24  (24  oxyethylene 
cholesteryl  ether)  were administered  intravenously to female  NMRI mice  bearing the 
MAC 15A subcutaneously implanted tumour. The results show that doxorubicin released 
from the niosomes was about 10 fold greater than the clearance of niosomal doxorubicin; 
the  area  under  the  plasma  level-time  curve  increased  6  fold  when  doxorubicin  was 
administered  in  niosomes,  compared  to  doxorubicin  solution  and the  modest  tumour 
targeting was achieved by the delivery of doxorubicin in sorbitan monostearate niosomes, 
increasing the tumour to heart area under curve for 24 hours  ratio from 0.27 to 0.36 and a 
doubling of tumoricidal activity. The overall level of doxorubicin metabolites was also 
increased.
Nasseri, 24 studied the mechanical characteristics of non-ionic bilayer membranes 
composed of sorbitan monostearate, cholesterol and poly-24-oxyethylene cholesteryl by 
measuring the modulus of surface elasticity (μ), a measure of membrane strength, as a 
function  of  cholesterol  content  and  temperature.  Study  suggests  an  increase  in  the 
membrane elasticity on addition of cholesterol but excess of cholesterol above 40% mol 
leads  to  decrease in the surface elasticity.  It  was due to  the  formation  of  cholesterol 
clusters at high cholesterol content where excess amounts of cholesterol cannot interact 
with  the  sorbitan  monostearate,  and  deposits  on  the  bilayers  compromising  their 
uniformity, strength and permeability.
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Fang et al., 6 studied on the skin permeation and partitioning in nude mouse skin 
of a fluorinated quinolone antibacterial agent, enoxacin in liposomes and niosomes. After 
topical application they observed the following permeation enhancer effect and the direct 
vesicle fusion with stratumcorneum, which may contribute to the permeation of enoxacin 
across  skin.  Formulation  with  niosomes  demonstrated  a  higher  stability  after  48  h 
incubation compared to liposomes and the inclusion of cholesterol improved the stability 
of enoxacin liposomes according to the results from encapsulation and turbidity.
Tabbakhian et al., 25 investigated enhancement of finasteride concentration at the 
pilosebaceous  unit  on  topical  application  in  the  form  of  vesicles  (liposomes  and 
niosomes) as compared to finasteride hydroalcoholic solution.  Liposomes consisted of 
phospholipid (dimyristoylphosphatidylcholine: cholesterol:  dicetylphosphate)  Niosomes 
comprised non-ionic surfactant (polyoxyethylene alkyl  ethers (Brij® series) or sorbitan 
monopalmitate):  cholesterol:  dicetylphosphate.  In  vitro permeation  of  H-finasteride 
through hamster flank skin was faster from hydroalcoholic solution. In vivo deposition of 
H-finasteride vesicles in hamster ear showed that liquid-state vesicle were able to deposit 
the applied dose to the pilosebaceous unit studies, demonstrate the potentials of liquid-
state liposomes and niosome for successful delivery of finasteride to the pilosebaceous 
unit.
Bandyopadhyay et al.,  26 studied on the self-organization of nonionic surfactant 
span 60 (sorbitan mono stearate) in presence of fatty alcohol (stearyl, cetyl and lauryl) 
Vesicular  suspension  had  been  characterized  by  transmission  electron  microscopy, 
dynamic light scattering, confocal laser scanning microscopy, dye entrapment and release 
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studies. Surface tension measurement indicates the suitability of fatty alcohols towards 
spontaneous vesicle formation from span 60.
Arunothayanun  et  al., 27 describes  an  early  prototype  of  a  pulsatile  delivery 
system for drug containing vesicles. Nonionic surfactant vesicles (niosomes) of average 
diameter 4-30 mm are extruded from glass capillaries using air pressures of 0.5-5 psi. 
Extrusion was affected by the size, shape, and membrane composition of the niosomes 
used. Spherical or polyhedral niosomes, formed by polyoxyethylene alkyl ethers with and 
without  cholesterol,  respectively,  with  diameters  larger  than  the  exit  diameter  of  the 
capillary do not retain their membrane integrity on extrusion and were sheared to form 
new ultra structures. They observed pulsatile expulsion of groups of niosomes entrapping 
LHRH which indicates the feasibility of this system for pulsatile delivery of vesicles, 
although it requires miniaturization.
Girigoswami  et  al., 28 found  that niosomal  vesicles  are  more  stable  than 
liposomal  vesicles  due  to  higher  chemical  stability  of  surfactants  compared  to 
phospholipids.  Niosome  had  been  prepared  from  Span20,  Span80,  Tween20  and 
Tween80. Fluorescence resonance energy transfer studies have been performed in these 
systems to determine donor–acceptor distances. It has been found that the fluorescence 
resonance  energy  transfer  efficiency  is  better  in  niosome  compared  to  micelles.  The 
formation of niosome is guided by the hydrophile–lipophile balance value of the nonionic 
surfactant
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Solanki et al., 29 investigated the combined influence of 3 independent variables 
in the preparation of piroxicam proniosomes by the slurry method. A 3-factor, 3-level 
Box-Behnken  design  was  used  to  derive  a  second  order  polynomial  equation  and 
construct  contour  plots  to predict  responses.  The independent  variables  selected were 
molar  ratio  of  Span  60:  cholesterol,  surfactant  loading,  and  amount  of  drug.  The 
transformed  values  of  the  independent  variables  and the  Percentage  drug entrapment 
(dependent  variable)  were  subjected  to  multiple  regressions  to  establish  a  full-model 
second-order  polynomial  equation.  F  was  calculated  to  confirm  the  omission  of 
insignificant terms from the full-model equation to derive a reduced-model polynomial 
equation  to  predict  the  percentage  drug entrapment  of  proniosome-derived  niosomes. 
Contour plots were constructed to show the effects of molar ratio of span 60: cholesterol, 
surfactant loading, and amount of drug on the percentage drug entrapment. A model was 
validated  for  accurate  prediction  of  the  percentage  drug  entrapment  by  performing 
checkpoint  analysis.  The  Box-Behnken  design  demonstrated  the  role  of  the  derived 
equation  and  contour  plots  in  predicting  the  values  of  dependent  variables  for  the 
preparation and optimization of   piroxicam proniosomes.
Satturwar et al.,  30 prepared Ketoconazole niosomes prepared by ether injection 
technique using surfactant (Tween 40 or 80), cholesterol and drug in five different ratios 
by weight, The niosomes were characterized for size, shape, entrapment efficiency and in 
vitro drug release (by exhaustive dialysis). The formulations were also tested for in vitro 
(cup-plate method) and  in vivo antifungal activity (in rabbits) and compared with free 
ketoconazole. The results of the present study indicate that niosomes have the potential to 
reduce the therapeutic dose of ketoconazole by improving its performance
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Jagtap et al., 31 formulated niosomes of Pentoxifylline characterized niosomes in 
terms of entrapment efficiency, particle size distribution, in vitro release and stability and 
investigate the bronchodilatory activity of plain and niosomal Pentoxifylline  in vivo in 
guinea pigs. Pentoxifylline was entrapped in niosomes by lipid layer hydration method 
using span 60, cholesterol and dicetyl phosphate. The entrapment efficiency of niosomes 
of Pentoxifylline according to them is 9.26 plus minus 1.93 percent giving a sustained 
release of drug over a period of 24h and better stability over the period of storage. The 
plain and niosomal Pentoxifylline produced significant bronchodilatory effect in guinea 
pigs on histamine-induced bronchoconstriction. The study indicates that Pentoxifylline 
may be an effective bronchodilator.
Fang et al., 5 studied the skin permeation of estradiol from various proniosome gel formulations 
across excised rat skin was investigated in vitro. The encapsulation efficiency and size of niosomal vesicles 
formed from proniosomes upon hydration were also characterized. Proniosomes with Span 40 and Span 60 
increased the permeation of estradiol across skin. Niosome suspension (diluted proniosomal formulations)  
and proniosome gel showed different behavior in modulating transdermal delivery of estradiol across skin. 
Presence or absence of cholesterol in the lipid bilayers of vesicles did not reveal difference in encapsulation 
and permeation of the associated estradiol. The results show the importance of types and contents of non-
ionic surfactant in proniosomes in the efficiency of transdermal estradiol delivery.
Pardakhty  et al., 32 prepared niosomes of polyoxyethylene alkyl ethers (BrijTM) 
for encapsulation of insulin by film hydration method. Without cholesterol, brij 35 and 
brij 58 did not form niosomes, apparently because of relatively large polar head groups in 
comparison with their  alkyl  chains.  The size of vesicles  depended on the cholesterol 
content, charge incorporation or hydrophilicity of surfactants. Entrapment of insulin in 
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bilayer structure of niosomes protected it  against proteolytic  activity of chymotrypsin, 
trypsin  and  pepsin  in  vitro. The  maximum  protection  activity  was  seen  in  brij 
92/cholesterol vesicles. The kinetic of drug release for most formulations could be best 
described  by  Baker  and  Lonsdale  equation  indicating  diffusion  based  delivery 
mechanism. These results indicate that niosomes could be developed as sustained release 
oral dosage forms for delivery of peptides and proteins such as insulin.
Arunothayanun et al., 33 studied the physicochemical and biological differences 
between  polyhedral  and  spherical:  tubular  niosomes  polyhedral  niosomes  undergo  a 
reversible  shape transformation  into spherical  structures on heating above their  phase 
transition  temperature.  The  viscosity  of  polyhedral  niosomes  at  room temperature  is 
higher than their spherical counterparts due to their faceted and relatively rigid shape, At 
room temperature, polyhedral niosomes possess more rigid gel phase membranes and are 
less osmotically sensitive; however, they are more permeable because of a lack of or low 
levels of cholesterol in their  membranes.  Polyhedral niosomes loaded with luteinising 
hormone releasing hormone nonetheless, slow the release of drug compared to solution, 
albeit to a small extent.
Ismail A. Attia et al., 34 prepared acyclovir niosomes in a trial to improve its poor 
and variable oral bioavailability. The nonionic surfactant vesicles were prepared by the 
conventional thin film hydration method. The lipid mixture consisted of cholesterol, span 
60, and dicetyl phosphate. The percentage entrapment was 11% of acyclovir used in the 
hydration process. The vesicles had an average size of 0.95 μm. Most of the niosomes 
have  unilamellar  spherical  shape.  In  vitro drug  release  profile  was  found  to  follow 
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Higuchi’s  equation  for  free  and  niosomal  drug.  The  niosomal  formulation  exhibited 
significantly retarded release compared with free drug. The in vivo study revealed that the 
niosomal dispersion significantly improved the oral bioavailability of acyclovir in rabbits 
after  a  single oral  dose of  40 mg kg  −1.  The niosomal  dispersion  showed significant 
increase  in  the  mean  residence  time  (MRT)  of  acyclovir  reflecting  sustained  release 
characteristics. In conclusion, the niosomal formulation could be a promising delivery 
system  for  acyclovir  with  improved  oral  bioavailability  and  prolonged  drug  release 
profiles.
Dinesh Shenoy et al., 35 investigated the in vitro release profile, stability and anti-
fertility  efficacy  of  some injectable,  biodegradable  formulations  of  Centchroman  The 
formulations included an in situ gelling preparation namely Poly(Lactide-co-Glycolide) 
(PLGA)-in-Triacetin prepared by solution method and niosomes were prepared by lipid 
layer  hydration method. These were evaluated for physicochemical characteristics like 
size distribution,  percentage entrapment,  in vitro drug release profiles and stability at 
different  conditions  of  storage.  In  vivo anti-fertility  activity  was  evaluated  in  female 
albino rats showing normal oestrous cycle  by giving a single dose of the formulation 
histopathological  sections  of  the  uterus  and ovary  were  also  done.  The  formulations 
showed controlled drug release and enhanced stability whereas  in-vivo studies showed 
promising anti-fertility activity for PLGA-in-Triacetin.
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Kaur  et  al., 16 reviews  the  constraints  with  conventional  ocular  therapy  and 
explores various novel approaches, in general, to improve ocular bioavailability of the 
drugs, advantages of vesicular approach over these and the future challenges to render the 
vesicular  system  more  effective.  The  discussion  covers  the  importance  of  niosomes 
liposome, discomes etc in ocular delivery.
Carafa et al., 36 formulated Non ionic surfactant vesicles entrapped lidocaine in 
the form of a free base and a hydrochloride. Non ionic surfactant vesicles were prepared 
from  polyoxyethylene  sorbitan  monolaurate  and  cholesterol.  The  effect  of  vesicle 
composition  and  environmental  pH  condition  on  drug  encapsulation  efficiency  was 
investigated. freeze-fracture microscopy technique, dynamic light scattering, permeation 
through Silastic and mouse abdominal skin, in vitro release kinetics of vesicle-entrapped 
drugs, fluorescence quenching analyses were also studied. Lidocaine HCl loaded vesicles 
showed a higher Permeation through mouse abdominal skin. Charged vesicles prepared 
in the presence of dicetylphosphate (DCP) and N-aetylpyridinium chloride showed low 
entrapment efficiency.
Almira  et al., 37 reported a novel method for rapid preparation of proniosomes 
with a wide range of surfactant loading. Slurry method has been developed by them to 
produce proniosomes using maltodextrin  as the carrier.  The time required to produce 
proniosomes by this simple method is independent of the ratio of surfactant solution to 
carrier material and appears to be scalable. The flexibility of the proniosome preparation 
method would allow for the optimization of drug encapsulation in the final formulation 
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based on the type and amount  of maltodextrin.  This formulation of proniosomes is a 
practical and simple method of producing niosomes at the point of use for drug delivery.
Sanyog et al., 38 developed mannosylated niosomes as oral DNA vaccine carriers 
for the induction of humoral,  cellular and mucosal immunity.  Niosomes composed of 
span 60,  cholesterol  and stearylamine  as constitutive  lipids  were prepared  by reverse 
phase evaporation method and were coated with a modified polysaccharide o-palmitoyl 
mannan.  The  coated  niosomes  were  found  to  be  better  stabilized  in  simulated  GIT 
conditions. The immune stimulating activity was studied by measuring serum anti-HBs 
Ag titer,  secretory IgA level in intestinal and salivary secretions. O-palmitoyl  mannan 
coated niosomes produced humoral (both systemic and mucosal)  and cellular immune 
response  upon  oral  administration.  The  study  signifies  the  potential  of  OPM  coated 
niosomes as DNA vaccine carrier and adjuvant for effective oral immunization.
Beugin et al., 39 have synthesized and characterized. Monomethoxypoly (ethylene 
glycol) cholesteryl carbonates (M-PEG-Chol) with polymer chain molecular weights of 
1000 (M-PEG1000-Chol) and 2000 (M-PEG2000-Chol). Their aggregation behavior in 
mixture with diglycerol hexadecyl ether (C16G2) and cholesterol has been examined by 
cryotransmission electron microscopy, high-performance gel exclusion chromatography, 
and  quasielastic  light  scattering.  Nonaggregated,  stable  unilamellar  vesicles  were 
obtained at low polymer levels with optimal shape and size homogeneity at cholesteryl  
conjugate/ lipids ratios of 10 mol% M-PEG1000-Chol. Higher levels up to 30 mol% lead 
to the complete solubilization of the vesicles into disc-like structures of decreasing size 
with increasing PEG content.  This study underlines  the bivalent  role of M-PEG-Chol 
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derivatives,  while behaving as solubilizing surfactants;  they provide an efficient steric 
barrier, preventing the vesicles from aggregation and fusion.
Naresh  et  al., 40 attempts  to  activate  and  exploit  macrophages  in  delivering 
niosomal  and  thermosensitive  niosomal  bleomycin  more  quantitatively  to  tumor  site 
using  niosome  encapsulated  immunomodulators  muramyl  dipeptide  and  tuftsin. 
Niosomal bleomycin  and thermosensitive niosomal  bleomycin  were prepared by lipid 
layer hydration method. The antitumor efficacy was assessed using two tumor models 
viz.  Sarcoma-180  and  Ehrlich  ascites  using  Balb/C  mice.  Accumulation  of  higher 
bleomycin levels after macrophage activation exerted increased antitumor effect. They 
suggest more quantitative delivery of bleomycin encapsulated in niosomes, to the tumor 
site is possible after macrophage activation.
Namdeo  et  al., 41 prepared  niosomes  of  5-fluorouracil  by  the  hand  shaking 
method, reverse phase evaporation and ether injection method using a series of Spans. 
Span 40 and span 60 showed a much sustained drug release. Introduction of cholesterol 
and dicetyl phosphate decreased the vesicle size and extended the release. The niosomal 
formulation shows increased half life AUC and a decrease in the volume of distribution. 
They suggest vesicles of 5 Fluorouracil as a promising drug deliver system.
Shahiwala  et al., 42 developed niosomal based trans-dermal delivery system of 
nimesulide, niosome prepared by lipid hydration technique using tweenss and spans. The 
formulations characterized for higher entrapment efficiency were incorporated in to 1% 
Carbapol  gel.  The highest  percentage  oedema inhibition  observed with niosomal  gel. 
Their investigation conclusively demonstrates prolongation of drug release and increase 
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in  the  amount  of  drug  retained  in  to  the  skin  and  permeation  across  the  skin  after 
niosomal encapsulation of nimesulide. Niosomal gel also demonstrated an enhanced anti 
inflammatory activity compared to plain drug gel and marketed formulation.
Parthasarathi  et  al., 43 prepared niosome  encapsulated  vincristine  sulfate  by 
transmembrane pH gradient. Drug uptake process (remote loading method) was evaluated 
for toxicity  and antitumour  activity  after  administration  to tumour  bearing mice.  The 
toxicity of vincristine sulfate was reduced after niosome encapsulation and anticancer 
activity improved, which may be due to better delivery of vincristine at the tumour site.
Uchegbu  et  al., 44 prepared  niosome  from  a  hexadecyl  diglycerol  ether  a 
hexadecyl  poly 5 oxyethylene ether sorbitan monosterate  in 1:1 ratio with cholesterol 
.span 60.  Niosomes were found to be stable both in 4oC and 240C retaining 75% of 
encapsulated material after 28 days. The incubation of niosome in plasma revealed the 
higher stability of it in plasma and the results suggest the possible release of drug only in 
the target site, that is drug available in vivo only after the cleavage of vesicle. 
Oommen  et al., 45 entrapped methotrexate complexed with b-Cyclodextrin into 
niosomes  by  lipid  layer  hydration  method.  To  characterize  niosomes  for  different 
physicochemical  properties  and  to  investigate  the  potential  of  niosome  entrapped 
methotrexate b-cyclodextrin complex in tumour treatment. The entrapment efficiency of 
the complex within the niosomes was determined by separating the un-entrapped drug 
using  dialysis.  The  niosomal  entrapment  efficiency  was  higher  in  the  case  of 
methotrexate b-cyclodextrin complex than with the plain drug. Comparison of the drug 
release in phosphate buffer revealed a relatively slow release pattern of the entrapped 
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drug  complex  from the  vesicles  as  compared  to  plain  MTX encapsulated  niosomes. 
Better stability on storage was also observed with the niosome entrapped complex. The 
complex entrapped niosomes  produced an improved anticancer  activity  as evident  by 
enhanced volume doubling time and growth delay.
Rentel et al., 46 developed a peroral vaccine delivery system based on non-ionic 
surfactant  vesicles  (niosomes)  were  evaluated  using  BALB:c  mice.  Ovalbumin  was 
encapsulated in various lyophilized niosome preparations consisting of sucrose esters, 
cholesterol  and dicetyl  phosphate.  Two different  formulations  were  compared  in  this 
study.  The specific  antibody titres  within  serum,  saliva  and intestinal  washings  were 
monitored by ELISA on days 7, 14, 21 and 28 after intragastric administration niosomes 
resulted  in  a  significant  increase  in  antibody titres.  Administration  of  ovalbumin  and 
empty niosomes did not exert a similar effect; neither did administration of any control 
formulation. In contrast to ovalbumin loaded Wasag 7 niosomes, application of the more 
hydrophilic  Wasag 15 niosome preparations  did not  result  in  an increase in  antibody 
titres.
Amelie  Bochot  et  al., 47 designed  an  ocular  delivery  system  based  on  the 
dispersion of liposomes into a thermo sensitive gel made of a copolymer  of ethylene 
oxide and propylene oxide (poloxamer 407). In order to stabilize liposomes in the gel, 
PEG2000-DSPE was introduced. Adsorption studies investigated by size and ζ-potential, 
measurements  have  shown  that  the  adsorption  was  higher  for  positively  charged  or 
neutral  non-  sterically  stabilized  liposomes.  Results  also  shown  that  liposome 
permeability was dramatically reduced in the presence of poloxamer 407, when PEG-
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DSPE was incorporated into the liposomes. The study suggests new system based on a 
dispersion  of  pegylated  liposomes  into  thermo  sensitive  poloxamer  407  is  proposed, 
offering new potentialities for delivery of drugs.
Elzainy et al., 48 Studied  the peripheral H1-antihistaminic activity and extent of 
systemic  absorption  of  cetirizine  from liposomes  applied  to  the  skin.  Cetirizine  was 
incorporated into small  unilamellar  vesicles  (SUV) and multilamellar  vesicles (MLV) 
prepared using L-α-phosphatidylcholine hydrogenated (HPC), and into Glaxal Base (GB) 
as the control. In a randomized, crossover study, each formulation, containing 10 mg of 
cetirizine, was applied to the depilated backs of 6 rabbits (3.08 ± 0.05 kg). Histamine-
induced wheal tests and blood sampling were performed before cetirizine application and 
at designated times for up to 24 hours afterwards. Compared with baseline, histamine-
induced wheal formation was suppressed by cetirizine in SUV only at 24 hours, in MLV 
from 0.5 to 24 hours, and in GB from 0.5 to 8 hours.
2. Vesicular Systems in Ocular Delivery 
Gholam A. Peyman et al., 49 had a discussion on delivery systems for intra ocular 
route. In brief; lntravitreal drug delivery has been developed to treat posterior segment 
diseases because the blood-ocular barrier prevents treatment by topical, systemic, or sub-
conjunctival  routes  from attaining  therapeutic  levels  in  the  vitreous.  Endophthalmitis, 
uveitis,  proliferative  vitreoretinopathy,  and  viral  retinitis  are  treated  by  intravitreal 
injection.  Efforts  to  sustain  drug  delivery  have  included  encapsulation  of  drugs  in 
liposomes (made of lipids) or microspheres (made of polymers). In many instances the 
drug’s toxicity to the retina was reduced and the clearance time was slowed. However, 
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these methods cause clouding of the vitreous and can prolong drug delivery for only one 
month. Implantable devices have been used, such as an osmotic minipump, a drug pellet 
coated with polyvinyl alcohol and ethylene vinyl acetate, and polysulfone capillary fiber. 
Biodegradable  devices  are  under  investigation,  including a  drug matrix  and a  porous 
reservoir  system,  both  made  of  polymers;  these  devices  would  not  require  surgical 
removal.
Rania  M.  Hathout  et  al.,  50 prepared  reversephase  evaporation  (REVs)  and 
multilamellar  (MLVs) acetazolamide  liposomes consisting of  egg phosphatidylcholine 
(PC) and cholesterol (CH) in molar ratio with or without stearylamine (SA) or dicetyl 
phosphate  (DP)  as  positive  and negative  charge  inducers,  respectively.  The prepared 
liposomes  were  evaluated  for  their  entrapment  efficiency  and  in  vitro  release. 
Multilamellar liposomes entrapped greater amounts of drug than REVs liposomes. Drug 
loading was increased by increasing CH content as well as by inclusion of SA. Drug 
release  rate  showed  an  order  of  negatively  charged  >  neutral  >  positively  charged 
liposomes,  which is the reverse of the data of drug loading efficiency.  From physical 
stability data the positively charged liposomes are less leaky neutral liposome retained 
least drug after the storage period of 3 months at 40C. The intraocular pressure (IOP)-
lowering activity of selected acetazolamide liposomal formulations was determined and 
compared  with  that  of  plain  liposomes  and  acetazolamide  solution.  Multilamellar 
acetazolamide  liposomes  revealed  more  prolonged  effect  than  REVs  liposomes.  The 
positively charged and neutral liposomes exhibited greater lowering in IOP and a more 
prolonged effect than the negatively charged ones.
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Vyas   et  al., 20 have prepared  non-ionic  surface  active  agents  based discoidal 
vesicles (discomes) bearing timolol maleate incorporated with Solulan C24 in order to 
effect vesicle to discome transition. The prepared system characterized for size, shape 
and drug release  profile  in  vitro.  They were  found to  release  the  contents  following 
biphasic profile particularly in the case where the drug was loaded using a pH gradient 
technique. The prepared system could produce or sustain a suitable activity profile upon 
administration into the ocular cavity; however, systemic absorption was minimized to a 
negligible level. The discomes were found to be promising and of potential for controlled 
ocular administration of water-soluble drugs.
Aggarwal  et  al., 51 prepared  Chitosan  or  Carbapol  coated  niosomal  timolol 
maleate formulation by reverse phase evaporation technique using span 60 and compared 
with the timolol maleate solution 0.25% in terms of in vitro release and I.O.P lowering. 
In-vitro release was extended significantly by the in corporation of the niosome and the 
further by polymer coating. The 0.25% timolol maleate niosomal formulation compared 
with  the  0.5% marketed  gel  formulation  the  result  showed  the  niosomal  preparation 
significantly better.
Law  et  al., 52 investigated the  in  vitro corneal  penetration and  in vivo corneal 
absorption of acyclovir from an acyclovir-containing liposome system. Results of in vitro 
corneal  penetration  demonstrated  that  positively  charged  liposomes  resulted  in  a 
penetration rate lower than those of negatively charged liposomes and free acyclovir in 
solution.  An  in  vivo study  indicated  that  the  extent  of  acyclovir  absorption  from 
positively charged liposomes was higher than those from negatively charged liposomes 
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and free  acyclovir.  The  acyclovir  concentration  in  the  cornea  after  administration  of 
positively charged liposomes was greater than those of negatively charged liposomes and 
free  acyclovir.  From  morphological  observation  of  the  cornea  surface  treated  with 
liposomes,  it  was  suggested  that  positively  charged  liposomes  formed  a  completely 
coated layer on the cornea surface leading to an increase of residence time. Therefore, 
positively charged liposomes resulted in an increase of acyclovir absorption.
Chetoni et al., 53 have studied ocular pharmacokinetics of topically administered 
acyclovir  liposome in comparison with commercial  acyclovir  ointment.  The acyclovir 
liposomal dispersion produced a significantly higher drug concentration profile  in the 
aqueous  humor  with  respect  to  the  three  reference  formulations  containing  the  same 
acyclovir  concentration.  In vitro release tests  substantiated the concept that  positively 
charged liposomal formulations owe their efficacy to interact with the positively charged 
corneal epithelium.
Budai et al., 54 developed ciprofloxacin containing liposomes and gel formulation 
to minimize the tear driven dilution in the conjunctival sac a long pursued objective of 
the ophthalmology. Physicochemical properties (pH, osmolarity, viscosity, expandability, 
membrane fluidity) and in vitro release of were studied. Electron paramagnetic resonance 
spectroscopy studied  to  find  the  molecular  interaction;  the  polymeric  hydrogel  (Poly 
methacrylic  acid  940NF)  in  the  preparation  ensured  the  steady  and  prolonged 
ciprofloxacin  release.  In  addition,  encapsulation  of  ciprofloxacin  in  to  the  liposomes 
prolonged  the  in-vitro release  of  the  anti  bacterial  agent  depending  on  the  lipid 
composition (α-L DPPC and lecithin).
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Guinedi et al., 55 prepared niosomes from Span 40 or Span 60 and cholesterol in 
the  molar  ratios  of  7:4,  7:6  and  7:7  using  reverse-phase  evaporation  and  thin  film 
hydration methods. The prepared systems were characterized for entrapment efficiency, 
size, shape and in vitro drug release. Stability studies were carried out to investigate the 
leaching of drug from niosome during storage. The intraocular pressure (IOP) lowering 
activity  of  acetazolamide  niosomal  formulations  in  rabbit  was  also  studied.  Higher 
entrapment efficiency reported by span 60 vesicles, the niosomes retained 75% of drug 
on storage in the refrigerated condition for 3 months. Span 60 and cholesterol in a 7:4 
molar ratio were found to be the most effective and showed prolonged decrease in IOP 
and showed only a slight ocular irritation.
Diebold et al., 56   evaluated in vitro and in vivo a colloidal nano-system with the 
potential  to deliver drugs to the ocular surface. They prepared nano-system, liposome 
chitosan  nanoparticle  complexes,  as  a  complex  between  liposomes  and  chitosan 
nanoparticles. The conjunctival epithelial cell line was exposed to several concentrations 
of  three  different  liposome  chitosan  nanoparticle  complexes  to  determine  the 
cytotoxicity.  Conjunctival  epithelial  cells  were  examined  by  confocal  microscopy. 
Eyeball  and lid tissues from liposome chitosan nanoparticle complexes treated rabbits 
were evaluated for the  in vivo uptake and acute tolerance of the nanosystems.  Strong 
cellular uptake liposome chitosan nanoparticle  in vivo and less intensive uptake by the 
corneal  epithelium  was  reported.  These  data  demonstrate  those  liposome  chitosan 
nanoparticles are potentially useful as drug carriers for the ocular surface.
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Omaima  et  al., 57 formulated  a  liposomal  preparation  of  acetazolamide  to  be 
applied topically, and evaluated it for  in vitro and  in vivo performance. Acetazolamide 
liposomes  were  prepared  using  the  reverse  phase  evaporation  technique.  Neutral, 
positively-charged and negatively-charged liposomes were evaluated for their entrapment 
efficiency,  drug release, and  in vivo activity.  The percent entrapment was higher with 
positively charged liposome and least with negatively charged one. The proportion of 
drug released after 9 hr was 13.36%, 33.8% and 26.7% for negatively-charged, neutral 
and positively-charged liposomes respectively.  They found a good correlation between 
the percent of inhibition of carbonic anhydrase activity and the amount of drug released.
Law  et  al., 58 investigated  loading  efficiency  and  release  characteristics  of 
acyclovir-containing liposomes. It was found that positively charged liposomes gave the 
highest loading efficiency. The neutral liposomes showed a loading efficiency in between 
those of the positively charged and negatively charged liposomes. Liposomes prepared by 
the method of drug–lipid film hydration presented a higher loading efficiency than that 
prepared by lipid film hydration with drug solution. For positively charged liposomes, the 
release rate was faster at higher molar ratios of stearylamine. However, for negatively 
charged liposomes, the release rate with a molar ratio of dicetylphosphate at 0.15 was 
greater than at 0.3. Decrease of mobility was found for positively charged liposomes after 
loading  with  acyclovir,  whereas,  no  significant  change  in  mobility  was  observed  for 
negatively charged and neutral liposomes.
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Thirumurthy  et  al., 59 evaluated the  retinal  toxicity  of  plain  and  liposomal 
formulation of flucanazole at various dose levels after intravitreal injection. The study 
conducted  in  the  New  Zealand  albino  rabbit  revealed  that  plain  flucanazole  at  a 
concentration of 100 µg and above caused retinal changes, with disorganization of the 
photoreceptor  outer  segments.  However,  liposome formulation  of  fluconazole  did  not 
show any significant microscopic changes of the retina.
Aggarwal  et  al.,  60 prepared  niosomes  of  acetazolamide  (by  reverse  phase 
evaporation method) and coated with Carbopol for the latter’s bioadhesive effect. The 
pharmacodynamic studies showed 33% fall in IOP with the developed formulation, and 
the effect was sustained for 6 hr after instillation. The aqueous humor disposition of the 
drug  from the  developed  bioadhesive  coated  niosomal  formulation  (ACZREVbio)  is 
compared with the aqueous suspension of the drug (containing 1% (w/v) Tween 80 as a 
dispersing agent) at similar concentrations. The concentration of acetazolamide absorbed 
in  the  aqueous  humor  at  various  times  from  the  control  suspension  and  from 
ACZREVbio  was  determined  by  microdialysis  in  male  albino  rabbits.  The  peak 
concentration of drug absorbed in the aqueous humor from the ACZREVbio formulation 
was  almost  two times  of  that  obtained  with  the  equivalent  amount  of  acetazolamide 
control suspension. The aqueous humor disposition indicates peaks and troughs in drug 
concentration which may be related to the decrease in aqueous humor formation, such 
that the drug concentration or volume increased at these points.
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Barber et al., 61 investigated on tear fluid induced release of liposome entrapped 
agents. Rabbit tear fluid was shown to promote the release of both an entrapped water 
soluble  dye  (5-carboxyfluorescein)  and  a  high  molecular  weight  protein 
(acetylcholinesterase)  from  multilamellar  liposome.  Heat  treatment  of  tear  fluid  was 
found to have no effect on the release of the enzyme but did reduce dye leakage. Pre-
incubation of the tear fluid with empty liposome was found to have no significant effect 
on  either  enzyme  or  dye  release.  Unlike  serum  where  liposome destabilization  is 
reportedly almost entirely the result of high density lipoproteins, our results suggest that 
multiple factors are involved in tear-mediated liposome destabilization.
3. Literatures on Diclofenac Sodium. 
Raja Naresh  et al., 62 entrapped diclofenac sodium in niosomes comprising of 
Tween 85 and Tween 85 poloxamer F 108 mixture. Anti- inflammatory efficacy of these 
niosomes was compared with that of free diclofenac sodium in adjuvant induced arthritic 
rats.  It  was  found  that  the  niosomal  diclofenac  sodium  formulations  prepared  by 
employing  a  1:l  combination  of  Tween 85 and poloxamer  F 108 elicits  a  better  and 
consistent anti-inflammatory activity for more than 72 hours after  administration of a 
single dose.
Turker et al., 63 describes a novel approach for designing drug delivery systems 
for intra-articular treatment of rheumatoid arthritis by liposome, niosome, lipogelosome 
and niogelosome formulations  of  diclofenac  sodium.  Retention  of  these  systems  was 
evaluated by radio labeling with Tc-99m and gamma scintigraphy in arthritic rabbits. The 
study results  show that  radio-labeled  lipogelosome  formulation  containing  diclofenac 
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sodium retained much longer in the experimentally arthritic knee joints of the rabbits. 
Great retention of diclofenac sodium in the arthritic joint said to reduce potential adverse 
systemic effects of the drug because of local administration into the diseased area. The 
study concludes as it is a promising drug delivery system for Intra-articular drug delivery.
Kao  Xiang  Sun  et  al., 64 prepared  diclofenac  sodium  cationic  liposomes  by 
reverse-phase  evaporation  method  and the  formula  of  liposome  were  optimized  with 
uniform design. HPLC method was established and validated for the determination of 
diclofenac sodium in precornea, cornea and aqueous humor of rabbit eye. Liposome and 
eye drop solution 50 microL with total 50 microg diclofenac sodium were instilled to 
eyes of rabbits, separately. Samples of tear, cornea and aqueous humor were collected at 
different time intervals after rabbits were sacrificed. The ocular pharmacokinetics was 
investigated  by  the  concentration-time  data  of  tear,  cornea  and  aqueous  humor. 
Diclofenac sodium cationic liposomes can increase the corneal contact time, enhance the 
corneal permeability of diclofenac sodium and improve its ocular bioavailability.
Katrin Kriwet et al., 65 studied the relation ship between the colloidal structure of 
a  topical  formulation  and  the  drug  release  in  vitro as  well  the  influence  of  the 
microstructure on the stratum corneum permeability. The study revealed drug transport 
across from the aqueous solution and from vesicles with a high effective diffusion co 
efficient  is  controlled  by  stratum  corneum.  The  intact  liposome  entrapped 
flouromicrography  of  cryo-section  of  human  skin  showed  no  deep  penetration  of 
diclofenac diethyl amine from intact liposome.
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Hwang et al., 66 examined Remote loading of the model drugs diclofenac, insulin 
and fluorescein isothiocyanate labeled insulin (FITC-insulin) into liposomes by formation 
of trans-membrane gradients.  A trapping efficiency of almost  100% was obtained for 
liposomal  diclofenac,  by  the  calcium  acetate  gradient  method,  where  as  liposomes 
prepared by the conventional reverse-phase evaporation vesicle method had low trapping 
efficiencies.  Soybean-derived  sterol  was  reported  to  be  better  stabilizer  of  the 
dipalmitoylphosphatidylcholine  bilayer  membrane  than  cholesterol.  The  work  has 
demonstrated a remote loading method for weak acids such as diclofenac into liposomes 
by the acetate gradient method. From the result of remote loading of FITC-insulin into 
liposomes  by  the  pH  gradient  method,  this  method  reported  for  the  preparation  of 
liposomal peptides.
Szucs  et  al., 67 conducted a  prospective,  randomized,  double blinded,  placebo-
controlled clinical trial. Consenting consecutive patients 49 in numbers with corneal were 
randomly assigned to receive either diclofenac or control vehicle drops. Pain relief was 
measured using a visual Numeric Pain Intensity Scale (NPIS) before and after treatment. 
25 of the patients received diclofenac and 24 received control vehicle drops. Both groups 
were similar in gender, age, pretreatment pain duration, NPIS score and analgesic use. 
There was significantly greater improvement in the 2-hour NPIS score in the diclofenac 
group  compared  with  the  control  group.  Study  concludes  by  saying  diclofenac 
ophthalmic  solution  appears  to  be  a  safe  and effective  analgesic  in  the  treatment  of 
traumatic corneal abrasions.                                       
58
Gennaro D'Angelo et al., 68 evaluated the efficacy of prolonged treatment with 
preservative-free  diclofenac  sodium  0.1%  eye  drops  in  patients  with  vernal 
keratoconjunctivitis. Study was performed in 22 patients with vernal keratoconjunctivitis 
treated with preservative-free diclofenac sodium 0.1% eye drops. Patients used the eye 
drops four times daily in both eyes for 120 days. Forty per cent of the patients showed an 
improvement in their symptoms at the end of the treatment. Total signs and symptoms 
scores were significantly decreased at the end of treatment compared with the baseline 
values.  Significant  decreases  in  conjunctival  redness,  itching  and  photophobia  were 
observed at the end of treatment. Conjunctival hyperaemia was significantly reduced at 
the end of treatment, while no significant differences were observed for corneal lesions 
and  for  papillary  size.  No  patient  showed  exacerbation  of  the  disease  during  the 
treatment.  Study demonstrates  the  efficacy  and  safety  of  preservative-free  diclofenac 
sodium 0.1% eye.
Reddy et al., 69 compared the effect of diclofenac sodium 0.1% following cataract 
surgery was to  routine  corticosteroid,  dexamethasone phosphate 1% in a  prospective, 
double-blind  randomized  study.  Groups  were  similar  in  baseline  parameters. 
Postoperative  inflammatory  response,  intraocular  pressure  and  best-corrected  visual 
acuity following standard extra capsular cataract extraction were assessed in both groups 
in the initial 21 days and the severity of these parameters was graded. The two groups did 
not differ statistically in treatment effect for any of the variables including aqueous cells, 
flare,  ciliary  congestion,  Descemet's  folds,  visual  acuity  and  intraocular  pressure. 
However, there seemed to be a trend towards quicker improvement with corticosteroid 
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when cells  in the anterior  chamber were considered.  There were no side effects  from 
topical diclofenac, and it was well tolerated.
Kocak  et  al., 70 performed  a  clinical  double-blind  study  in  patients  who  had 
undergone extra capsular cataract extraction and intraocular lens implantation to compare 
the anti-inflammatory  effects  of  diclofenac  sodium 0.1% and flurbiprofen  0.03% eye 
drops. The diclofenac group included 21 eyes of 21 patients and the flurbiprofen group 
included  22  eyes  of  22  patients.  The  parameters  compared  were  pachymetry  of  the 
cornea, corneal surface changes, intraocular pressure and the degree of inflammation of 
the anterior chamber at one, three and six weeks after cataract surgery. There was no 
statistically  significant  difference  between  the  two  treatment  groups  in  corneal 
pachymetry, corneal surface changes and the anterior chamber inflammation. Both drugs 
were well tolerated and may be safely used to reduce inflammation for cataract surgery.
Carl  P.  Herbort  et  al., 71 compared  the  anti-inflammatory  effect  of  topical 
diclofenac  sodium  0.1%  in  a  fixed  combination  with  gentamicin  0.3%  to  the  anti- 
inflammatory  effect  of  dexamethasone  phosphate  0.1%  in  a  prospective  randomized 
double  masked  double-dummy  study  in  patients  undergoing  cataract  surgery.  Eighty 
seven patients were recruited, 45 being assigned to the diclofenac group and 42 to the 
dexamethasone control group. Diclofenac was significantly better than dexamethasone at 
controlling  flare  at  day  3  and  day  12–14.  Mean  anterior  chamber  cells  were  also 
significantly lower at day 12–14 and day 28. The commonest adverse event was transient 
punctate keratitis, which occurred in 15 diclofenac and 3 dexamethasone patients. While 
both treatments were effective at controlling post-operative inflammation, the diclofenac-
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gentamicin  combination  followed  by  diclofenac  alone  was  significantly  better  at 
suppressing flare and cells but showed a slightly higher incidence of punctate keratitis 
and eye discomfort.
Palmero et  al., 72 studied  the  ocular  pharmacokinetics  of  topical  diclofenac 
sodium  in  two  experimental  models  of  ocular  inflammation,  and  compared  to 
physiological  conditions.  Keratitis  or uveitis  was induced by intrastromal  injection of 
clove  oil  or  by  intravitreal  lipopolysaccharide  in  rabbits.  The  control  eyes  were  not 
inflamed, simultaneously to the induced of inflammation 30 µl of 0.1% diclofenac were 
applied topically in the right eye. In physiological conditions, diclofenac reached a peak 
level in the cornea and iris ciliary body (ICB) at 30 min slowly decreasing afterwards. 
Low levels of diclofenac were found in AH. In keratitic eyes Diclofenac concentrations 
in keratitic AH and ICB were lower than in controls. In uveitic eyes, corneal and ICB 
levels peaked at 30 min, being significantly higher than in controls and decreased quickly 
to very low levels at 1 h after application. In uveitic AH, diclofenac levels were lower 
than in controls. Plasma levels were very low in all experimental groups. It is concluded 
that  the  ocular  pharmacokinetics  of  topical  diclofenac  is  affected  by  inflammatory 
processes in the eye, reaching higher levels in the target tissues.
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DRUG PROFILE73-80
Diclofenac Sodium 
Formula:             
C14H11Cl2NO2Na 
IUPAC name:      
2- [2-(2, 6-dichlorophenyl) aminophenyl] ethanoic acid 
Molecular weight:  
318.14 g 
Category: 
Anti inflammatory, Analgesic 
Description:  
 Faintly  yellow  white  to  light  beige,  slightly  hygroscopic 
crystalline powder 
Melting point: 
2800C  
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Solubility: 
 
Freely soluble in Methanol, sparingly soluble in Water, very slightly soluble in 
Acetonitrile and insoluble in Chloroform and 0.1 N Hydrochloric acid.  
Indication: 
Diclofenac  sodium  0.1%  ophthalmic  solution  indicated  for  treatment  of  post 
operative inflammation in patient who have under gone cataract extraction, and temporary 
relief of pain and photophobia in patients under gone corneal refractive surgery. 
Dose:
Cataract surgery:  One drop should be applied to the affected eye,  four times daily, 
beginning 24 hours after surgery and continuing through out the first two weeks of the 
post operative period.
Corneal refractive surgery:  One or two drops should  be applied to the operative eye 
within the hour prior to surgery, within 15 minutes after surgery, one or two drops should 
be added to the operative eye and continued 4 times daily for up to 3 days.
Mode of action:
It has analgesic, antipyretic and anti inflammatory activities. It is an inhibitor of 
cyclooxygenase and its  potency is substantially greater than that of indomethacin and 
naproxen  or  several  other  agents.  In  addition  diclofenac  sodium  appears  to  reduce 
intracellular concentration of free arachidonic acid in leukocytes perhaps by altering the 
release or up take of fatty acid. 
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Pharmacokinetics: 
Diclofenac sodium rapidly and completely absorbed on oral administration; peak 
concentration in plasma reaches within 2-3 hours. Administration with food slows the 
rate but doesn’t alter the extent of absorption. There is substantially first pass metabolism 
such that only about 50% of diclofenac sodium is available systematically. The drug is 
extensively bound to plasma protein(99%) and its half life in plasma is 1-2 hours. The 
volume  of  distribution  of  drug  is  0.17  liters/kg.  Diclofenac  sodium  accumulates  in 
synovial fluid after oral administration, which may explain the duration of therapeutic 
action  of  that  is  considerably higher  than  the  plasma half  life.  Diclofenac  sodium is 
metabolized  in  the  liver  by  cytochrome  P-450  isozyme  of  CYP2C  subfamily.  
2-hydroxydiclofenac,  the  principle  metabolite  and  other  hydroxylated  forms;  after 
glucoronidation and sulfation the metabolite were excreted in urine (65%) and bile (35). 
0.01% is the total fraction of drug that excreted through urine in its original form. Plasma 
levels  of  diclofenac  sodium  following  ocular  instillation  of  two  drops  of  diclofenac 
sodium ophthalmic solution, 0.1% to each eye were below the limit of quantization (10 
ng  /  mL)  over  a  4-hour  period.  This  study  suggests  that  limited,  if  any,  systemic 
absorption occurs with diclofenac sodium ophthalmic solution, 0.1%.
Contra indication: 
 Hypersensitivity against Diclofenac sodium. 
 History of allergic reactions (bronchospasm, shock, rhinitis, urticaria) following 
the use of Aspirin or another NSAID 
 Third-trimester pregnancy 
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 Active stomach and/or duodenal ulceration or gastrointestinal bleeding 
 Inflammative intestinal disorders such as Crohn's 
disease or ulcerative colitis 
 Severe insufficiency of the heart (NYHA III/IV) Recently, a warning has been 
issued by FDA not to treat patients recovering from heart surgery 
 Severe liver insufficiency (Child-Pugh Class C) 
 Severe renal insufficiency (creatinine clearance <30 ml/min)
 Caution in patients with preexisting hepatic porphyria, as diclofenac sodium may 
trigger attacks 
 Caution in patients with severe, active bleeding such as cerebral hemorrhage 
Adverse reaction
Diclofenac  sodium is  among  the  better  tolerated  NSAIDs.  Though  20%  of 
patients on long-term treatment experience side effects, only 2% have to discontinue the 
drug, mostly due to gastrointestinal complaints. 
Ocular: Transient burning and stinging was reported in 15% of patients with the 
use of topical diclofenac sodium ophthalmic solution, 0.1% In cataract studies, keratitis 
occurred  in  28% of  patients  receiving  diclofenac  sodium  ophthalmic  solution  0.1%, 
however,  most  of  the  cases  of  keratitis  occurred  prior  to  drug  therapy.  Elevated 
intraocular  pressure  was  reported  in  15%  of  patients  receiving  diclofenac  sodium 
ophthalmic  solution,  0.1%.  The  following  adverse  reactions  were  reported  in 
approximately 5% or less of the patients:  abnormal vision, anterior  chamber reaction, 
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blurred vision, conjunctivitis, corneal deposits, corneal edema, corneal lesions, corneal 
opacity, discharge, injection, iritis, irritation, itching and ocular allergy.
Systemic: The  following  adverse  reactions  were  reported  in  3%  or  less  of  the 
patients:  abdominal  pain,  asthenia,  chills,  dizziness,  facial  edema,  fever,  headache, 
insomnia, nausea, pain, rhinitis, viral infection, and vomiting
Precautions: 
General: It is recommended that Diclofenac Sodium Ophthalmic Solution,  0.1%, 
like  other  NSAIDs,  be  used  with  caution  in  surgical  patients  with  known  bleeding 
tendencies  or  who  are  receiving  other  medications  that  may  prolong  bleeding  time. 
Diclofenac Sodium Ophthalmic Solution, 0.1% may slow or delay healing. Diclofenac 
Sodium Ophthalmic Solution, 0.1% has no significant effect upon intraocular pressure; 
however, elevations in intraocular pressure may occur following cataract surgery.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Long term therapy in rats by 
oral  diclofenac  sodium up to  2  mg/kg/day  (approximately  the  human  oral  dose)  has 
revealed  no  significant  increases  in  tumor  incidence.  There  was  a  slight  increase  in 
benign  rat  mammary  fibro  adenomas  in  mid-dose  females  (high  dose  females  had 
excessive mortality) but the increase was not significant for this common rat tumor. In 
mice employing oral diclofenac sodium up to 2 mg/kg/day for 2 years did not reveal any 
oncogene  potential.  Diclofenac  sodium  did  not  show  mutagenic  potential  in  various 
mutagencity studies including the Ames test.  Diclofenac sodium administered to male 
and female rats at 4 mg/kg/day did not affect fertility.
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Teratogenic effect: In mice at oral doses up to 5000 times (20 mg/kg/day) and in rats and rabbits at oral  
doses  up  to  2500  times  (10  mg/kg/day)  of  the  human  topical  dose  have  revealed  no  evidence  of  
teratogenicity due to diclofenac sodium, despite the induction of maternal toxicity and fetal toxicity. In rats,  
maternally  toxic  doses  were  associated  with  dystocia,  prolonged  gestation,  reduced  fetal  weights  and 
growth, and reduced fetal survival. Diclofenac sodium has been shown to cross the placental barrier in mice 
and rats.
Nonteratogenic  effects:  Because of  the  known effects  of  prostaglandin  biosynthesis-
inhibiting  drugs  on  the  fetal  cardiovascular  system  (closure  of  the  ductus 
arteriosus), the use of Diclofenac Sodium Ophthalmic Solution, 0.1% during late 
pregnancy should be avoided.
Pediatric: Safety and effectiveness in pediatric patients have not been established.
Over dose                  
The maximum daily dose of diclofenac sodium is 200 mg. Over dosage will not 
ordinarily cause acute problems. If accidentally ingested, fluids should be taken to dilute 
the medication.
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RESEARCH ENVISAGED
1. Aim of Work
Diclofenac Sodium, a drug which widely accepted for its safety and efficacy in 
the treatment of anterior segment eye inflammation and as prophylaxis, against cystoid’s 
macular edema is used in this study. The low bioavailability, low solubility and short half 
life of this drug make it a candidate for control delivery. 
Niosomes, synthetic microscopic vesicles consisting of an aqueous concentration 
enclosed in a bilayer consisting of cholesterol and one or more nonionic surfactants, have 
been  reported  as  a  possible  approach  to  improve  the  low  corneal  penetration  and 
bioavailability characteristic shown by conventional ophthalmic vehicles. 
In  this  work a  potential  drug delivery system of  diclofenac  sodium entrapped 
niosomes for ocular delivery have been developed and characterized. 
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2. Plan of Work
The present work was carried out to prepare and evaluate niosomal drug delivery 
system of diclofenac sodium with non ionic surfactant, span 60, in various proportions. 
The  following  experimental  protocol  was  therefore  designed  to  allow  a  systemic 
approach to the study. 
 Procurement of drug and raw materials.
 Preparation of standard curves. 
 Formulation of niosomes. 
 Evaluation of niosomes for the following physico-chemical parameters.
 Microscopy.
 Encapsulation efficiency and drug loading. 
 In-vitro release study.
 Drug release kinetic data analysis.
 Stability study.
 Test for significance.
 Zeta potential analysis.
 In- vivo drug release study. 
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MATERIALS AND INSTRUMENTS 
Materials Used 
The following materials  were used for the research  work in  their  best  quality 
available.
Table no. 3
Materials used for the research work 
S.No. Name Grade Company Name
1. Diclofenac sodium Pharma Novaratis Limited, India
2. Cholesterol  L.R Loba Chem Pvt. Ltd., Mumbai  
3. Span 60 L.R Loba Chem. Pvt. Ltd., Mumbai  
4. Chloroform L.R Loba Chem Pvt. Ltd., Mumbai    
5. Methanol L.R S.D.Fine Chem Ltd., Mumbai
6. Sodium acetate L.R Loba Chem Pvt. Ltd., Mumbai
7. Ethyl acetate L.R S.D.Fine Chem Ltd., Mumbai
8. Sodium chloride L.R Loba Chem Pvt. Ltd., Mumbai
9. Potassium di-hydrogen phosphate L.R S.D.Fine Chem Ltd., Mumbai
10. Sodium hydroxide L.R Nice chemicals Pvt. Ltd., Cochin
11. Di. Sodium hydrogen phosphate L.R S.D. Fine Chem Ltd., Mumbai
12. Xylocaine 4% L.R Astra Zenica Ltd., India
13. Distilled water L.R Leo Scientific, Erode
14. H.P.L.C. water. H.P.L.C Qualigens, India
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Table no.  4
Instruments used for the research work
S.No. Name Company Name
1. Rotary flash evaporator Super fit, India ltd.
2. Cooling centrifuge Remi Motors Ltd, Mumbai.
3. Electronic digital balance Schimadzu, Japan.
4. HPLC system Schimadzu, Japan.
5. Dialysis membrane 50 Hi media, India
6. pH meter. Systronioc, Chennai
7. Double beam UV/VIS Spectrophotometer. ELICO, Mumbai
8. Zeta Potential Probe (model DT-300) Zetasizer 4, France. 
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EXPERIMENTAL PROCEDURES
1. Niosome Preparation 42
The niosome formulations were prepared by lipid film hydration technique. Drug 
(Diclofenac  sodium),  non  ionic  surfactant  and  cholesterol  were  weighed  (surfactant: 
cholesterol  in  µmol)  and  dissolved  in  chloroform methanol  (2:1)  in  a  100 ml  round 
bottom flask.  A thin  lipid  film was formed  under  reduced pressure  in  a  rotary flash 
evaporator. The film was then hydrated by 10 ml of PBS1 pH 7.4 at room temperature 
with gentle shaking. The niosome suspension further hydrated up to 24 hrs at 2-80 C. The 
stabilized MLVs were used for further studies. 
Table no. 5 
Compositions of Niosomal batches of Diclofenac sodium
Formulation
No.
Ratio(µmol) 
(surfactant: cholesterol)
Surfactant 
(mg)
Cholesterol 
(mg)
F 1 200:200 86 77.32
F 2 200:175 86 67.66
F 3 200:150 86 57.9
F 4 200:125 86 48.32
F 5 200:115 86 44.45
F 6 200:100 86 38.66
F 7 200: 85 86 32.8
F 8 200: 75 86 28.19
F 9 150:200 64.5 77.32
F10 150:150 64.5 57.9
F11 150:125 64.5 48.32
Drug content used 10 mg per batch 
1  2.38 gm of Di-sodium hydrogen phosphate, 0.19gm of potassium di-hydrogen phosphate 
and 8.0 gm of sodium chloride were weighed accordingly and made up to 1000 ml with distilled 
water.79
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2. Characterization of Niosomes 
Preparation of standard curve of Diclofenac sodium in PBS
100 mg of Diclofenac sodium was dissolved in 100 ml of pH 7.4 phosphate buffer 
saline solution to the concentration of 1000µg/ml. 1 ml of this solution was taken and 
made up to 100 ml with buffer solution which contains the concentration of 10  µ g/ml, 1 
to 10 ml were taken from this solution and made up to 10 ml to get the concentration 
ranges  of  1  to  10µg/ml.  The absorbance  of  the  above said  solutions  were  measured 
against  the  phosphate  buffer  saline  pH  7.4  as  blank  at  275  nm  using  UV 
spectrophotometer.63 Then the calibration curve was plotted taking concentration on X-
axis and absorbance on Y-axis.
2.1. Entrapment efficiency 81
Niosome entrapped diclofenac  sodium was estimated  by dialysis  method.  The 
prepared  niosomes  were  placed  in  the  dialysis  bag  50  (presoaked  for  24  hrs).  Free 
diclofenac sodium was dialyzed for 30 minutes each time in 100 ml of phosphate buffer 
saline  pH 7.4.  The  dialysis  of  free  diclofenac  sodium always  completed  after  12-15 
changes,  when  no  Diclofenac  was  detectable  in  the  recipient  solution.  The  dialyzed 
diclofenac sodium was determined by finding out the concentration of bulk of solution by 
UV spectrophotometer  at  275 nm. The samples  from the bulk of solution diluted ten 
times before going for absorbance measurement. The free diclofenac sodium in the bulk 
of solution gives us the total amount of un-entrapped drug. Encapsulation efficiency is 
expressed as the percent of drug trapped.        
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                                        Total drug – Diffused drug 
    Percent Entrapment =                                                          × 100
                                                             Total drug 
2.2. Microscopy 
The  vesicle  formation  by  the  particular  procedure  was  confirmed  by  optical 
microscopy in 400x resolution. The niosome suspension placed over a glass slide and 
fixed  over  by  drying  at  room temperature,  the  dry  thin  film of  niosome  suspension 
observed  for  the  formation  of  vesicles.  The photomicrograph  of  the  preparation  also 
obtained from the microscope by using a digital SLR camera.
2.3. In-vitro drug release study 
Preparation of standard curve of diclofenac sodium 
Preparation of pH 7.4 Phosphate Buffer 80
50.0  ml  of  0.2  M potassium di-hydrogen  phosphate  was  placed  in  a  200  ml 
volumetric flask, added the specified volume of 39.1 ml of 0.2 M sodium hydroxide and 
then made up to the volume by water.
Potassium di-hydrogen phosphate, 0.2 M
27.218 gm of potassium di-hydrogen phosphate was dissolved in distilled water 
and diluted to 1000 ml.
0.2M sodium hydroxide solution
8 gm of sodium hydroxide was dissolved in distilled water and diluted to 1000ml.
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Standard Curve of Diclofenac Sodium
100mg of diclofenac sodium was dissolved in 100ml of pH 7.4 phosphate buffer 
solution which gives the concentration of 1000µg/ml. 1ml of this solution was taken and 
made up to 100ml with buffer solution which contains the concentration of 10  µ g/ml,  
1 to 10ml were taken from this solution and made up to 10ml to get the concentration 
ranges  of  1  to  10µg/ml.  The absorbance  of  the  above said  solutions  were  measured 
against the phosphate buffer pH 7.4 as blank at 280 nm using UV spectrophotometer. 65 
Then the calibration curve was plotted taking concentration on X-axis and absorbance on 
Y-axis.
Release Study 51
In vitro release pattern of niosomal suspension was carried out in dialysis  bag 
method. 2 mg equivalent of 0.1% of niosomal suspension was taken in dialysis bag (Hi 
media) and the bag was placed in a beaker containing 100 ml simulated tear fluid (pH7.4 
phosphate buffer). The beaker was placed over magnetic stirrer and the temperature was 
maintained at 37+10C. 5 ml samples were withdrawn periodically and were replaced by 
fresh  buffer.  The  sink  condition  was  maintained  through  out  the  experiment.  The 
withdrawn samples were diluted two times and analyzed for drug content  using U.V. 
spectrophotometer at 280 nm keeping phosphate buffer pH 7.4 as blank.
2.3.1 Drug Release Kinetic Data Analysis.
The release data obtained from various formulations were studied further for their 
fitness in the zero order release pattern. The study was conducted by checking the fitness 
of data in models like Higuchi’s and peppa’s.
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2.4. Stability Study
2.4.1. Physical stability 55
Physical stability study was carried out to investigate the leaching of drug from 
niosome  (in  a  suspension)  during  storage.  Best  three  (F4,  F5,  F6)  of  the  optimized 
diclofenac  niosomal  suspension composed of  span-60 and cholesterol  sealed  in  glass 
vials and stored in refrigerated temperature(2-80C) for a period of  3 months. Samples 
from each batch were withdrawn after the definite time intervals and the residual amount 
of drug in the vesicles was determined. Stability data of three formulations were further 
analyzed for significant difference by paired t-test.
2.4.2 Zeta potential analysis
Zeta potential was analyzed to measure the stability of niosome by studying its 
colloidal property. The study was conducted using zeta potential probe (model DT-300). 
The  formulation  F6  which  was  found to  have  a  better  physical  stability,  was  further 
analyzed by this method for its vesicular stability.
2.5 In Vivo Study 83-86 
Male  albino  rabbits  10-12  weeks  old,  weighing  2.5-3.5  kg  were  used  in  the 
present study.  They were housed individually with husk bedding and fed with standard 
pellet  diet  and  water  as  much  required.  The  temperature  was  maintained  at  28+20C 
through out the study. The study protocol was approved by Institutional Animal Ethical 
Committee for the use of animal in research (Proposal No.NCP/IAEC/PG/03/2007-2008).
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Two healthy rabbits  were used for the study.   Three  drops of 0.1% niosomal 
suspension of diclofenac sodium was instilled in the lower cul-de-sac of each eye. The 
upper eyelids were gently held closed for 10 seconds to maximize the corneal contact. At 
the 4th  and 8th  hour of post dose, eyes were anesthetized using 4% Xylocaine solutions 
topically and the aqueous humor was sampled from 4 eyes by using a 26 gauge needle.  
The aqueous humor from each eye extracted by introducing a 26 gauge needle between 
the  junction  of  sclera  and  cornea.  After  the  extraction  the  eyes  were  treated  with 
ciprofloxacin eye drops for the prevention of infection.  Sampled Aqueous humor was 
then mixed with 100 µl of ethyl acetate and kept in the refrigerator for one hour. The 
mixture was then centrifuged at 3000 rpm for 20 minutes and the supernatant obtained 
was  analyzed  for  the  presence  of  diclofenac  sodium  by  HPLC-  U.V  detector,  by 
comparing with the retention time of a standard solution (50 µg/ml).
Apparatus for chromatographic condition 
Qualitative  estimation  of  diclofenac  sodium was  done by HPLC.  Filtered  and 
degassed mixture of methanol and sodium acetate 0.1 M (60:40) was used as mobile 
phase.  The  equipments  include  following,  Shimdazu  HPLC  pump  and  detector, 
Phenominax C18,  5µ column (250x4.6mm) and fixed volume injector (10µl). The mobile 
phase delivered in rate of 1 ml/min the effluents analyzed in 254 nm. A single 50µg/ml 
solution of drug in the mobile  phase injected as sample.  A blank was run after each 
injection to ensure the reliability.
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RESULT AND DISCUSSION 
Various  niosomal  formulations  of  diclofenac  sodium  using  span  60  and 
cholesterol were prepared. The prepared formulations were further characterized for the 
percentage drug entrapment by dialysis method. 
1. Entrapment Efficiency
1.1 Standard curve of diclofenac sodium in phosphate buffer saline pH 7.4
Table no. 6
Standard curve of diclofenac sodium in PBS pH 7.4
S.No.
Concentration
µg/ml
Absorbance at
275 nm
1
2
3
4
5
6
7
8
9
1
2
3
4
5
6
7
8
9
0.034
0.054
0.094
0.120
0.155
0.189
0.211
0.251
0.268
       
R2      = 0.988
Slope = 0.0285
Graph no. 1
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1.2 Entrapment efficiency of various formulations
Entrapment efficiency was studied for all the 11 formulations to find the best in 
terms of entrapment efficiency. Higher entrapment efficiency of the vesicles of span 60 is 
predictable because of its higher alkyl chain length. The entrapment efficiency was found 
to  be  higher  with  the  formulation  no.  F6  (82.10%),  which  may  have  an  optimum 
cholesterol  surfactant  ratio  to  provide  a  high  entrapment  of  diclofenac  sodium.  The 
niosomal  formulations  having  high  surfactant  concentration  (F6,  F4  and  F5)  have  the 
higher entrapment efficiency which might be due to the high fluidity of the vesicles. Very 
low cholesterol content (F8) was also found to cause low entrapment efficiency (57.89%), 
which might be because of leakage of the vesicles. It was also observed that very high 
cholesterol  content  (F9)  had  a  lowering  effect  on  drug  entrapment  to  the  vesicles 
(44.91%). This could be due to  the fact  that  cholesterol  beyond a certain level  starts 
disrupting the regular bi-layered structure leading to loss of drug entrapment. The higher 
entrapment may be explained by high cholesterol content (~50% of the total lipid). There 
are reports that entrapment efficiency was increased, with increasing cholesterol content 
and by the usage of span-60 which has higher phase transition temperature. The larger 
Standard curve of Diclofenac sodium in PBS pH 7.4
0
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vesicle  size  may  also  contribute  to  the  higher  entrapment  efficiency.  Entrapment 
efficiency showed by various formulations are specified in Table no.7. 
Table no. 7 
Entrapment efficiency of various formulations
S.No. Formulation no
Molar ratio
(span60 :  Cholesterol)
Entrapment efficiency* 
%
1 
2
3
4
5
6
7
8
9
10
11 
F1
F2
F3
F4
F5
F6
F7
F8
F9 
F10
F11
200:200
200:175
200:150
200:125
200:115
200:100
200: 85
200: 75
150:200
150:150
150:125
62.10 ± 1.32 
63.85 ± 1.27 
68.07 ± 0.47 
70.87 ± 0.32 
77.89 ± 0.88
82.10 ± 0.92 
63.86 ± 0.41
57.89 ± 0.58 
44.91 ± 1.18 
67.10 ± 0.75 
58.45 ± 0.52 
*Average of three formulations, ± S.D. 
2. MICROSCOPY
The  prepared  vesicles  were  studied  under  400x  magnification  to  observe  the 
formation of vesicles. Some unevenness of vesicles that observed under the study may be 
due  to  drying  process  under  normal  environment  condition.  The  photomicrograph  of 
niosomes is shown in the figure below. The particles found to be uniform in size and 
shape. 
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Figure no. 6 Photomicrograph of niosome in a dry glass slide 
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3.  IN-VITRO RELEASE PROFILE 
3.1. Standard curve of Diclofenac sodium in phosphate buffer pH 7.4 
Table No.8
Standard cure of Diclofenac sodium in phosphate buffer pH 7.4
S.NO Concentration Absorbance at 280 nm
1
2
3
4
5
6
7
8
9
1 µg/ml
2 µg/ml
3 µg/ml
4 µg/ml
5 µg/ml
6 µg/ml
7 µg/ml
8 µg/ml
9 µg/ml
0.027
0.058
0.088
0.126
0.145
0.182
0.223
0.235
0.276
Graph no.3
Slope: 0.0308                                               R 2    : 0.997
Diclofenac sodium standard curve in 
phosphate buffer pH 7.4
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3.2. Release profile of various formulations.
The  release  study  was  conducted  for  all  the  11  formulations.  Most  of  the 
formulations  were found to have a linear  release and the formulations  were found to 
provide approximately 60% release within a period of 10 hours. The formulations which 
have high cholesterol ratio (F9,  F10) were found to sustain the drug release. Cholesterol, 
which has a property to abolish the gel to liquid transition of niosomes, this found to 
prevent the leakage of drug from the niosomal formulation. The slower release of drug 
from multilamellar  vesicles  may  be  attributed  to  the  fact  that  multilamellar  vesicles 
consist of several concentric sphere of bilayer separated by aqueous compartment. The 
above specified three best formulations F4, F5, and F6,  were found to give a cumulative 
release of 64.04%, 64.17% and 70.01% respectively over a period of 10 hrs, the higher 
release  from  the  formulation  F6 may  be  because  of  its  low  cholesterol  content. 
Formulations  F1,  F9  and F10 having the highest  cholesterol  content  showed the lowest 
release  over  10  hours,  they  provide  a  release  of  59.42%,  52.47%  and  56.43% 
respectively.
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Table No.9
In vitro release profile of formulation F1
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 280 
nm
Conc. in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.034 1.10 0.22 11.04 11.60 1.064
2 1.41 0.301 0.041 1.33 0.27 13.31 13.59 1.133
3 1.73 0.477 0.053 1.72 0.34 17.21 17.54 1.244
4 2.00 0.602 0.070 2.27 0.45 22.73 23.16 1.365
5 2.24 0.699 0.085 2.76 0.55 27.60 28.17 1.450
6 2.45 0.778 0.105 3.41 0.68 34.09 34.78 1.541
7 2.65 0.845 0.123 3.99 0.80 39.94 40.79 1.611
8 2.83 0.903 0.144 4.68 0.94 46.75 47.75 1.679
9 3.00 0.954 0.161 5.23 1.05 52.27 53.44 1.728
10 3.16 1.000 0.179 5.81 1.16 58.12 59.42 1.774
Graph No.4 
In vitro release profile of formulation F
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Graph no.5
Graph no.6
Higuchi's plot for formulation F
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Table no.10
In vitro release profile of formulation F2
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 
280 
nm
Conc. in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.028 0.91 0.18 9.09 9.56 0.980
2 1.41 0.301 0.041 1.33 0.27 13.31 13.54 1.132
3 1.73 0.477 0.050 1.62 0.32 16.23 16.57 1.219
4 2.00 0.602 0.062 2.01 0.40 20.13 20.54 1.313
5 2.24 0.699 0.082 2.66 0.53 26.62 27.13 1.433
6 2.45 0.778 0.097 3.15 0.63 31.49 32.16 1.507
7 2.65 0.845 0.111 3.60 0.72 36.04 36.83 1.566
8 2.83 0.903 0.132 4.29 0.86 42.86 43.76 1.641
9 3.00 0.954 0.149 4.84 0.97 48.38 49.45 1.694
10 3.16 1.000 0.173 5.62 1.12 56.17 57.38 1.759
Graph no.7
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Graph no.8
In vitro  release profile of formulation F
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Graph no.9
Higuchi's plot for formulation F
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Table no.11
In vitro release profile of formulation F3
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. at 
280 nm
Conc. 
in
(µg/ml)
Conc.
in 100 ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1 0.000 0.025 0.81 0.16 8.12 8.53 0.931
2 1.41 0.301 0.035 1.14 0.23 11.36 11.57 1.063
3 1.73 0.477 0.047 1.53 0.31 15.26 15.54 1.192
4 2 0.602 0.064 2.08 0.42 20.78 21.16 1.326
5 2.24 0.699 0.082 2.66 0.53 26.62 27.14 1.434
6 2.45 0.778 0.100 3.25 0.65 32.47 33.13 1.520
7 2.65 0.845 0.120 3.90 0.78 38.96 39.77 1.600
8 2.83 0.903 0.141 4.58 0.92 45.78 46.75 1.670
9 3 0.954 0.158 5.13 1.03 51.30 52.44 1.720
10 3.16 1.000 0.173 5.62 1.12 56.17 57.45 1.759
Graph no.10
In vitro  release profile of formulation F
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Graph no.11
Graph no.12
Table no.12
Higuchi's plot for formulation F
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In vitro release profile of formulation F4
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 280 
nm
Conc. 
in
(µg/ml)
Conc.
in 100 ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.034 1.10 0.22 11.04 11.60 1.064
2 1.41 0.301 0.044 1.43 0.29 14.29 14.56 1.163
3 1.73 0.477 0.064 2.08 0.42 20.78 21.14 1.325
4 2.00 0.602 0.076 2.47 0.49 24.68 25.19 1.401
5 2.24 0.699 0.094 3.05 0.61 30.52 31.14 1.493
6 2.45 0.778 0.111 3.60 0.72 36.04 36.80 1.566
7 2.65 0.845 0.135 4.38 0.88 43.83 44.73 1.651
8 2.83 0.903 0.152 4.94 0.99 49.35 50.45 1.703
9 3.00 0.954 0.170 5.52 1.10 55.19 56.43 1.751
10 3.16 1.000 0.193 6.27 1.25 62.66 64.04 1.806
Graph no.13
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Graph no.14
Graph no.15
Higuchi's plot for formulation F
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Table no.13
In vitro release profile of formulation F5
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 
280 
nm
Conc. 
in
(µg/ml)
Conc.
in 100 ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.025 0.80 0.16 8.00 8.41 0.925
2 1.41 0.301 0.038 1.24 0.25 12.37 12.57 1.099
3 1.73 0.477 0.062 2.00 0.40 19.98 20.29 1.307
4 2.00 0.602 0.076 2.47 0.49 24.73 25.23 1.402
5 2.24 0.699 0.097 3.14 0.63 31.39 32.01 1.505
6 2.45 0.778 0.120 3.90 0.78 39.00 39.79 1.600
7 2.65 0.845 0.135 4.38 0.88 43.76 44.73 1.651
8 2.83 0.903 0.149 4.85 0.97 48.52 49.61 1.696
9 3.00 0.954 0.170 5.52 1.10 55.18 56.39 1.751
10 3.16 1.000 0.193 6.28 1.26 62.79 64.17 1.807
Graph no.16
Graph no. 17
In vitro  release profile of formulation F
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Graph no. 18 
Higuchi's plot for formulation F
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 Table no.14
In vitro release profile of formulation F6
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 
280 
nm
Conc. 
in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.037 1.20 0.24 12.01 12.63 1.101
2 1.41 0.301 0.053 1.72 0.34 17.21 17.51 1.243
3 1.73 0.477 0.067 2.18 0.44 21.75 22.18 1.346
4 2.00 0.602 0.082 2.66 0.53 26.62 27.17 1.434
5 2.24 0.699 0.103 3.34 0.67 33.44 34.11 1.533
6 2.45 0.778 0.126 4.09 0.82 40.91 41.75 1.621
7 2.65 0.845 0.144 4.68 0.94 46.75 47.78 1.679
8 2.83 0.903 0.164 5.32 1.06 53.25 54.42 1.736
9 3.00 0.954 0.185 6.01 1.20 60.06 61.40 1.788
10 3.16 1.000 0.211 6.85 1.37 68.51 70.01 1.845
Graph no.19
In vitro  release profile of formulation F
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Graph no.20
Graph no. 21
Higuchi's plot for formulation F
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Table no.15
In vitro release profile of formulation F7
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. at 
280 nm
Conc. 
in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.043 1.40 0.28 13.96 14.72 1.168
2 1.41 0.301 0.061 1.98 0.40 19.81 20.15 1.304
3 1.73 0.477 0.081 2.63 0.53 26.30 26.79 1.428
4 2.00 0.602 0.103 3.34 0.67 33.44 34.10 1.533
5 2.24 0.699 0.129 4.19 0.84 41.88 42.72 1.631
6 2.45 0.778 0.144 4.68 0.94 46.75 47.80 1.679
7 2.65 0.845 0.170 5.52 1.10 55.19 56.36 1.751
8 2.83 0.903 0.185 6.01 1.20 60.06 61.44 1.788
9 3.00 0.954 0.199 6.46 1.29 64.61 66.11 1.820
10 3.16 1.000 0.217 7.05 1.41 70.45 72.07 1.858
Graph no .22
In vitro  release profile of formulation F
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Graph no. 23
Graph no. 24
Table no.16
Higuchi's plot for formulation F
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In vitro release profile of formulation F8
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 280 
nm
Conc. in
(µg/ml)
Conc. in 
100 ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum% 
release
1 1.00 0.000 0.049 1.600 0.320 16.00 16 1.204
2 1.41 0.301 0.070 2.283 0.457 22.83 23.23 1.366
3 1.73 0.477 0.091 2.949 0.590 29.49 30.06 1.478
4 2.00 0.602 0.111 3.615 0.723 36.15 36.89 1.567
5 2.24 0.699 0.135 4.376 0.875 43.76 44.66 1.650
6 2.45 0.778 0.158 5.137 1.027 51.37 52.46 1.720
7 2.65 0.845 0.182 5.898 1.180 58.98 60.26 1.780
8 2.83 0.903 0.196 6.374 1.275 63.74 65.21 1.814
9 3.00 0.954 0.214 6.944 1.389 69.44 71.04 1.851
10 3.16 1.000 0.229 7.420 1.484 74.20 75.94 1.880
Graph no. 25
Graph no. 26
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Graph no. 27
Table no.17
Higuchi's plot for formulation F
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In vitro release profile of formulation F9
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 280 
nm
Conc. 
in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log cum
% 
release
1 1.00 0.000 0.028 0.909 0.182 9.09 9.09 0.959
2 1.41 0.301 0.038 1.234 0.247 12.34 12.56 1.099
3 1.73 0.477 0.047 1.526 0.305 15.26 15.57 1.192
4 2.00 0.602 0.059 1.916 0.383 19.16 19.54 1.291
5 2.24 0.699 0.070 2.273 0.455 22.73 23.21 1.366
6 2.45 0.778 0.091 2.955 0.591 29.55 30.11 1.479
7 2.65 0.845 0.105 3.409 0.682 34.09 34.83 1.542
8 2.83 0.903 0.123 3.994 0.799 39.94 40.79 1.611
9 3.00 0.954 0.144 4.675 0.935 46.75 47.75 1.679
10 3.16 1.000 0.158 5.130 1.026 51.30 52.47 1.720
Graph no. 28
In vitro  Release profile of formulation F
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Graph no. 29
Graph no. 30
Table no.18
Higuchi's plot for formulation F
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In vitro release profile of formulation F10
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs at 
280 
nm
Conc. in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum% 
release
1 1.00 0.000 0.034 1.104 0.221 11.04 11.04 1.043
2 1.41 0.301 0.047 1.526 0.305 15.26 15.54 1.191
3 1.73 0.477 0.059 1.916 0.383 19.16 19.54 1.291
4 2.00 0.602 0.070 2.273 0.455 22.73 23.21 1.366
5 2.24 0.699 0.082 2.662 0.532 26.62 27.19 1.434
6 2.45 0.778 0.101 3.279 0.656 32.79 33.46 1.524
7 2.65 0.845 0.114 3.701 0.740 37.01 37.83 1.578
8 2.83 0.903 0.135 4.383 0.877 43.83 44.76 1.651
9 3.00 0.954 0.152 4.935 0.987 49.35 50.45 1.703
10 3.16 1.000 0.170 5.519 1.104 55.19 56.43 1.751
Graph no. 31
In vitro release profile of formulation F
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Graph no. 32
Graph no. 33
Higuchi's plot for formulation F
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Table no.19 
In vitro release profile of formulation F11
Time 
in 
hour
Sqrt. 
of 
time
Log 
time
Abs. 
at 280 
nm
Conc. 
in
(µg/ml)
Conc.
in 100 
ml
(Mg/ml)
Percent
release
cum%
release
Log 
cum%
release
1 1.00 0.000 0.034 1.10 0.221 11.04 11.04 1.043
2 1.41 0.301 0.051 1.66 0.331 16.56 16.83 1.226
3 1.73 0.477 0.063 2.05 0.409 20.45 20.87 1.319
4 2.00 0.602 0.078 2.53 0.506 25.32 25.84 1.412
5 2.24 0.699 0.092 2.99 0.597 29.87 30.50 1.484
6 2.45 0.778 0.111 3.61 0.723 36.15 36.90 1.567
7 2.65 0.845 0.129 4.19 0.837 41.86 42.76 1.631
8 2.83 0.903 0.149 4.85 0.970 48.52 49.56 1.695
9 3.00 0.954 0.170 5.52 1.104 55.18 56.39 1.751
10 3.16 1.000 0.185 5.99 1.199 59.93 61.31 1.788
Graph no. 34
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Graph no. 35
Graph no. 36
Higuchi's plot for formulation F
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3.3 Drug release kinetic data 
The  zero  order  plots  showed  the  zero  order  release  characteristics  of  the 
formulation,  which  was  confirmed  by the  correlation  value.  In  order  to  find  out  the 
mechanism  of  drug  release,  the  in  vitro drug  release  data  was  graphically  treated 
according to Higuchi’s equation and the graphical fit for the  in vitro data was used to 
conclude the mechanism of the drug release involved in the delivery system. Correlation 
value of Higuchi’s plot revealed that the mechanism of drug release is diffusion. The 
correlation value of zero order plots and correlation value of Higuchi’s plot presented in 
table  no.  22.  The  in  vitro kinetic  data  subjected  to  log  time  log  drug  release 
transformation plot (peppa’s model), all the value ranges from 1 to 1.2704 revealed the 
fact that the drug release follows a super case II transport diffusion. The slop value for 
each formula presented in table below. 
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Table no. 20
Drug release kinetic data
Formulations
Zero order Higuchi’s Peppa’s
Slope Correlation  Slope Correlation Slope Correlation 
F1 5.682
6
0.9956 18.297
3
0.9542 1.204
0
0.8691
F2 5.356
7
0.9952 17.792
2
0.9511 1.207
4
0.9823
F3 5.717
3
0.9974 18.899
5
0.9487 1.270
4
0.9039
F4 6.054
3
0.9970 20.257
1
0.9598 1.226
7
0.8696
F5 6.248
3
0.9989 28.931
4
0.9938 1.000
0
0.9040
F6 6.559
9
0.9967 21.974
8
0.9607 1.235
8
0.8613
F7 6.932
9
0.9943 23.471
5
0.9797 1.239
2
0.8448
F8 7.288
7
0.9929 25.084
8
0.9832 1.238
6
0.8341
F9 5.006
8
0.9945 16.606
4
0.9491 1.189
8
0.8846
F10 5.220
6
0.9947 17.571
6
0.9633 1.166
1
0.8589
F11 5.827
0
0.9967 19.614
4
0.9653 1.210
7
0.8652
4. STABILITY STUDY
4.1 Physical stability
Physical stability was carried out to investigate the leaching out of the diclofenac 
sodium from niosomes at  refrigerated temperature,  as shown in the graph no: 2. The 
percent of diclofenac retained in the span 60 vesicle after a period of three months were 
82.47%, 78.32% and 76.43% respectively for formulations F4 (200:125), F5 (200:115) and 
F6  (200:100).  Also the results  indicate  that  more than 80% of diclofenac sodium was 
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retained  in  the  niosomal  formulation  for  a  period  of  60  days.  From  this  it  can  be 
concluded that vesicles are stable enough to store under refrigeration temperature with 
least leakage. The leakage of drug from F6 may be due to its higher surfactant content and 
lower cholesterol which formed a leaking vesicle. 
            
Table No.21
Percentage of diclofenac sodium retained on refrigerated storage
S.No. Days
Stored
F4
Percent retained
F5
Percent retained
F6
Percent retained
1
2
3
4
5
15
30
45
60
90
98.35
95.32
92.66
87.22
83.47
97.33
94.23
90.26
86.37
78.32
97.42
93.75
89.84
84.79
76.43
Graph No. 2   
Percentage of diclofenac sodium retained in the niosome formulations after storage 
at refrigeration temperature
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4.2. Test of Significance
The stability data analyzed for significant difference between retention patterns of 
drug  in  three  different  niosomal  formulations  on  storage.  The  test  value  showed  no 
significant  difference  (P>0.05)  between  the  stability  data  of  formulations  from each 
other.
Table No: 22 
Test of Significance
Formulations F4-F5 F5-F6 F4-F6
P-value 0.060484 0.084811 0.050935
4.3. Zeta potential analysis
The formulation F6 which was subjected to zeta potential analysis had a zeta value 
of +29mv,  which is  a measure of net charge of niosomes.  This higher charge on the 
surface  of  vesicle  produce  a  repulsive  force  between  the  vesicles  which  made  them 
stable,  devoid  of  agglomeration  and  faster  settling,  providing  an  evenly  distributed 
suspension.  From this  it  can  be  concluded  that  formulation  F6 provides  much  stable 
Niosomal suspension. 
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5. IN-VIVO STUDY
The prepared niosomes of diclofenac sodium studied for its prolonged release  
in vivo  in the animal  model  Rabbit  (n=2).  In vivo study conducted to investigate  the 
ocular availability of drug for a prolonged action after a single dose. The study carried 
out by comparing the retention time of the standard drug solution to that of the aqueous 
humors extracted sample. The retention time obtained for the standard was 4.52 minutes, 
for  the  samples  at  4th  and 8th  hour  were  4.780  and  4.660  minutes  respectively.  This 
matching  retention  time  of  three  injections  to  HPLC  showed  the  presence  of  drug 
diclofenac  sodium  in  the  aqueous  humor  sample  even  after  4 th  and  8th hour  of 
administration. In other words drug was available in detectable quantities even after 8th 
hour of administration, where as the literature says, concentration of diclofenac sodium in 
aqueous  humor  will  be  in  undetectable  quantity  after  4th hr  of  administration  as 
conventional  ocular  drops.  This  may be  because  of  possible  retention  of  drug in  the 
aqueous  humor  due  to  high  corneal  contact  time  and  permeability  provided  by  the 
vesicular system.
101
H.P.L.C peak for standard solution  
Fig no. 7:  Standard HPLC peak of diclofenac sodium with retention time at 4.520
102
 HPLC peak for sample at 4th hour 
Fig no:8 Sample peak at 4th hour after drug administration having a retention time 
of 4.780 min.
103
HPLC peak for sample at 8th hour 
Fig no : 9  Sample peak at 8th hour after administration of drug having retention 
time of 4.660 min.
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CONCLUSION
Recently niosomes have been studied by many workers as a choice of ocular drug 
delivery system to provide a better ocular bioavailability considering, high penetration 
property  of  the  niosome  encapsulated  agents  through  biological  membrane  and  the 
stability of them.
The present  formulation  study on diclofenac  sodium is  an  attempt  to  prepare 
niosomal  drug  delivery  system and  evaluate  its  performance.  The  formulations  were 
prepared with different ratios of cholesterol and surfactant.
An  ideal  or  best  formulation  of  niosome  is  said  to  be  one  which  gives  high 
entrapment  efficiency.  In  this  study  entrapment  efficiency  is  found  to  be 
cholesterol:surfactant  ratio  dependent.  The release rate  also found to be dependent  of 
cholesterol:surfactant  ratio.  The  formulation  F6, which  showed  a  higher  entrapment 
efficiency provides a comparatively less leaky niosome this fact confirms the above said. 
Zeta  potential  study  proved  that  the  above  formulation  have  an  excellent  stability.  
Formulations also found to ensures a good ocular bioavailability of the drug in vivo.
By these facts study can be concluded by saying niosomes formed from span 60 
and cholesterol in the ratio 200:100 (in  µmol) is a promising approach to improve the 
bioavailability of diclofenac sodium even for an extended period of time. 
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